

I. OVERVIEW OF THE FUNDING OPPORTUNITY

United States Army Medical Research and Development Command



DEPARTMENT OF DEFENSE

**BROAD AGENCY ANNOUNCEMENT
for Extramural Medical Research**

Funding Opportunity Number: W81XWH18SBAA1

Announcement Type: Modified

**Catalog of Federal Domestic Assistance Number: 12.420
Military Medical Research and Development**

KEY DATES

Release/Posted Date: October 1, 2017

Closing Date: September 30, 2022, 11:59 p.m. Eastern Time

This funding opportunity announcement is a broad agency announcement (BAA). It is continuously open for a 5-year period, from October 1, 2017 through September 30, 2022, 11:59 p.m. Eastern Time.

This Broad Agency Announcement must be read in conjunction with the General Submission Instructions, which are available for downloading from Grants.gov. The General Submission Instructions are located under the “package tab” and can be downloaded by selecting the “Download Instructions” icon when previewing the submission package.

Table of Contents

I. OVERVIEW OF THE FUNDING OPPORTUNITY	1
I.A. New for Fiscal Year 2018 – Fiscal Year 2022	4
II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY.....	5
II.A. Program Descriptions.....	6
II.A.1. Military Infectious Diseases Research Program.....	6
II.A.2. Combat Casualty Care Research Program	7
II.A.3. Military Operational Medicine Research Program.....	9
II.A.4. Medical Biological Defense Research Program.....	10
II.A.5. Medical Chemical Defense Research Program	11
II.A.6. Radiation Health Effects Research Program	12
II.A.7. Other Information.....	13
II.B. Award Information	17
II.B.1. Funds Available and Anticipated Number of Awards.....	17
II.B.2. Award Amounts and Periods of Performance	17
II.B.3. Mechanisms of Support	17
II.C. Eligibility Information.....	20
II.C.1. Eligible Applicants	20
II.C.2. Cost Sharing	21
II.C.3. Other	21
II.D. Proposal/Application Submission Information	22
II.D.1. Where to Obtain the Proposal/Application Submission Package.....	22
II.D.2. Content and Form of Proposal/Application Submission for Research Awards Not Including a Clinical Trial	22
II.D.3. Dun and Bradstreet Data Universal Numbering System (DUNS) Number and System for Award Management	42
II.D.4. Submission Dates and Times	42
II.D.5. Intergovernmental Review	42
II.D.6. Funding Restrictions.....	43
II.D.7. Other Submission Requirements	43
II.E. Proposal/Application Review and Selection Information	43
II.E.1. Criteria for Research Proposals/Applications Not Including a Clinical Trial.....	43
II.E.2. Proposal/Application Selection Process	46
II.E.3. Integrity and Performance Information	47
II.E.4. Notification of Proposal/Application Review Results.....	47
II.F. Federal Award Administration Information	47
II.F.1. Federal Award Notices.....	47
II.F.2. Administrative and National Policy Requirements.....	48
II.F.3. Reporting Requirements	49

II.G. Federal Awarding Agency Contacts	49
II.G.1. eBRAP Help Desk.....	49
II.G.2. Grants.gov Contact Center	49
II.H. Other Information.....	50
II.H.1. Contractor/Recipient Qualification	50
II.H.2. Proprietary Information.....	50
II.H.3. Administrative Actions.....	50
II.H.4. Common Submission Problems	52
II.I. Checklist for Research Proposal/Application Submission Not Including a Clinical Trial	53
APPENDIX I: RESEARCH AREAS OF INTEREST	55
I. Military Infectious Diseases Research Program	55
II. Combat Casualty Care Research Program	56
III. Military Operational Medicine Research Program.....	58
IV. Medical Biological Defense Research Program.....	61
V. Medical Chemical Defense Research Program	63
VI. Radiation Health Effects Research Program	65
APPENDIX II: CLINICAL TRIALS.....	66
A. Important Aspects of Clinical Trials.....	66
B. Full Proposal/Application Submission Components	67
C. Review Criteria for Research Proposals/Applications Including a Clinical Trial	84
D. Checklist for Research Proposal/Application Submission Including a Clinical Trial.....	89
APPENDIX III: DOD AND VA WEBSITES.....	91
APPENDIX IV: PROCEDURES FOR ACQUISITION, PROCESSING, STORAGE, AND SHIPMENT OF BIO-FLUIDS	93
APPENDIX V: NATIONAL INSTITUTE OF MENTAL HEALTH DATA ARCHIVE — INFORMED CONSENT	94
APPENDIX VI: TECHNOLOGY READINESS LEVELS AND KNOWLEDGE READINESS LEVELS.....	95
APPENDIX VII: ACRONYMS AND ABBREVIATIONS.....	96

I.A. New for Fiscal Year 2018 – Fiscal Year 2022

The Fiscal Year 2018 – Fiscal Year 2022 (FY18 – FY22) U.S. Army Medical Research and Development Command’s (USAMRDC) Broad Agency Announcement (BAA) for Extramural Medical Research contains several changes from previous USAMRDC BAAs. Read each section carefully. Note the following:

- The open period of the BAA has been extended to 5 years and will be amended annually with any updates.
- The format of the BAA has been revised to conform to Chapter II of Title 2, Code of Federal Regulations, Section 200.203 (2 CFR 200.203), “Notices of funding opportunities.”
- The “Research Areas of Interest” can be found in [Appendix I](#).
- The type of instrument used to reflect the business relationship between the organization and the government is at the discretion of the government, in accordance with the Federal Grant and Cooperative Agreement Act of 1977, as amended, United States Code, Title 31, Sections 6301-6308 (31 USC 6301-6308), which provides the legal criteria to select a procurement contract or an assistance agreement. The award type, along with the start date, will be determined during the negotiation process.
- For assistance agreements:
 - The total period of performance may be proposed for up to a maximum of 4 years in length; additional periods may be considered.
 - Any assistance agreement (grant or cooperative agreement) awarded under this BAA will be governed by the award terms and conditions that conform to the Department of Defense’s (DOD) implementation of Office of Management and Budget guidance in 2 CFR part 200, “Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards.” DOD implementation is located in Chapter XI of 2 CFR.
- For contract awards:
 - The total period of performance may be proposed for up to 5 years in length.
- For other transactions:
 - Regarding Other Transaction Agreements (OTAs) that utilize the authority within 10 USC 2371 and 2371(b), the period of performance will be dependent upon each specific award made.

II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY

The USAMRDC's mission is to provide solutions to medical problems of importance to the American Service Member at home and abroad, as well as to the general public at large. The scope of this effort and the priorities attached to specific projects are influenced by changes in military and civilian medical science and technology (S&T), operational requirements, military threat assessments, and national defense strategies. Extramural research and development programs play a vital role in the fulfillment of the objectives established by the USAMRDC. General information on the USAMRDC can be obtained at <https://mrdc.amedd.army.mil/index.cfm>.

This BAA is intended to solicit extramural research and development ideas using the authority provided by 10 USC 2358. The BAA is issued under the provisions of the Competition in Contracting Act of 1984 (Public Law 98-369), as implemented in Federal Acquisition Regulation (FAR) 6.102(d)(2) and 35.016 and in Department of Defense Grant and Agreement Regulations (DoDGARs) 22.315. In accordance with FAR 35.016, projects funded under this BAA must be for basic and applied research to support scientific study and experimentation directed toward advancing the state-of-the-art or increasing knowledge or understanding rather than focusing on development of a specific system or hardware solution. Research and development funded through this BAA are intended and expected to benefit and inform both military and civilian medical practice and knowledge. This BAA utilizes competitive procedures in accordance with 10 USC 2302(2)(B) for the selection for award of S&T proposals/applications. For the purposes of this BAA, S&T includes activities involving basic research, applied research, advanced technology development, and, under certain conditions, may include activities involving advanced component development and prototypes.

The selection process is highly competitive, and the quantity of meaningful submissions (both pre-proposals/pre-applications and full proposals/applications) received typically exceeds the number of awards that available funding can support.

This BAA provides a general description of USAMRDC's research and development programs, including Research Areas of Interest, evaluation and selection criteria, pre-proposal/pre-application and full proposal/application preparation instructions, and general administrative information. Specific submission information and additional administrative requirements can be found in the document titled, "General Submission Instructions," which is available on Grants.gov along with this BAA.

Proposal/application submission by extramural organizations through Grants.gov requires use of the Workspace interface, which separates the proposal/application package into individual forms. Applicants must create a Workspace in Grants.gov, complete the required forms, and submit their proposal/application Workspace package.

The management agent for this BAA is the Congressionally Directed Medical Research Programs (CDMRP). The CDMRP manages the electronic Biomedical Research Application Portal (eBRAP) system, pre-proposal/pre-application and full proposal/application receipt and

review, and other key process oversight. Refer to [Section II.G, Agency Contacts](#), for additional information.

The USAMRDC's supporting acquisition office, the U.S. Army Medical Research Acquisition Activity (USAMRAA), will be the awarding and administering office for proposals/applications selected for funding, unless approval is obtained from the USAMRAA Senior Contracting Official to allow another federal acquisition office to execute and administer an award.

II.A. Program Descriptions

II.A.1. Military Infectious Diseases Research Program

Infectious diseases pose a significant threat to the operational effectiveness of current and future U.S. Forces. Current and future forces must be prepared to deploy globally and (potentially) on short notice. The U.S. Armed Forces may be called on to operate in areas of the world where infectious diseases present substantial and immediate health risks to U.S. military personnel. Current national military strategy specifies a worldwide force protection capability that requires surveillance, prevention, diagnosis, and treatment to protect the U.S. Armed Forces against potential infectious disease threats. Future operational scenarios pose increased impact of IDs as natural environmental disease barriers become degraded, enabling rapid spread of diseases across dense urban environments and the population existing within. For example, highly communicable bacterial and viral diseases, multi-drug resistant organisms, and vector-borne diseases will pose significant challenges in dense urban environments during multi domain operations.

The mission of the Military Infectious Diseases Research Program (MIDRP) is to plan, coordinate and oversee for the DOD requirements-driven medical solutions that PREVENT, PREDICT, and TREAT infectious diseases threats to the total force maximizing Warfighter readiness and performance.

Vision of the MIDRP is to defeat infection:

- Prevent naturally-occurring infectious disease threats to eliminate their impacts on operational readiness of DOD personnel.
 - Prevention is the most desirable Infectious Disease Countermeasure because it prevents disease from occurring (vs. treatment post-infection), is the most cost-effective approach, and reduces unit loss rate.
- Treat naturally-occurring infectious disease threats to eliminate their impacts on operational readiness of DOD personnel.
 - Diagnosis centers on identifying the infectious disease and is integral in recommending treatment. Improved diagnosis and treatment of infectious disease casualties is necessary to protect the U.S. Armed Forces. Due to the ever increasing resistance to presently available treatments, continued countermeasure development needs to be pursued.

Proposals/applications that include a multidisciplinary approach combining the fields of human and veterinary medicine, entomology, and environmental science (One Health) are encouraged.

Research Areas of Interest to the MIDRP are found in [Appendix I.I](#). *Applicants are urged to read and consider these before preparing their proposals/applications.*

II.A.2. Combat Casualty Care Research Program

The Combat Casualty Care Research Program (CCCRP) provides integrated capabilities for current and future operations to reduce the mortality and morbidity associated with major combat-related trauma across the spectrum of combat casualty care, including point-of-injury and pre- or out-of-hospital care, the spectrum of en route care, and facilities-based treatment. A primary emphasis of the CCCRP is to identify and develop medical techniques, knowledge products, and materiel¹ (medical devices, drugs, and biologics) for early intervention in life-threatening battle injuries and prolonged care (PC).² Because battlefield conditions impose severe constraints on available manpower, equipment, and medical supplies available for casualty care, the CCCRP places an emphasis on medical interventions that can be used within the battle area or as close to it as possible before or during medical evacuation. Preferred medical techniques and materiel that can be used by combat medics must be easily transportable (i.e., small, lightweight, and durable in extreme environments and handling). Devices must be easy to use and require low maintenance, with self-contained power sources as necessary. The CCCRP is interested in existing technologies for which concept and/or patient care efficacy have already been demonstrated, but require improvement to meet military requirements. Development and validation of in vitro and in vivo assessment models that represent military-relevant conditions in wounded Service Members, as well as those that incorporate a systems biology approach, are of interest to the CCCRP when they can be used to identify and describe the safety and efficacy of novel technologies in patients in a predictable manner.

Research efforts are needed in principles, therapies, and technologies to enhance self- and buddy-aid, also referred to as tactical care; techniques, methods, or materiel to improve basic and advanced life support for all injured persons; monitoring, sustainment, and management of all injured casualties during episodes of delayed care or PC; and enhanced capability for triage of large numbers of casualties and staged treatment in the field. The principal causes of death among Service Members who die within the first hour of wounding are hemorrhage and traumatic brain injury (TBI). TBI can also occur as a result of blast injuries sustained during training.

The CCCRP supports additional aspects of casualty care. These include drugs, devices, and/or novel surgical techniques to decontaminate, debride, protect, monitor, repair, and/or stabilize complex bone and soft tissue wounds to mitigate secondary tissue damage; improvements to blood products and blood product delivery; novel solutions for non-compressible hemorrhage;

¹ Materiel is defined as equipment and supplies of a military force.

² PC is defined as field medical care, applied beyond “doctrinal planning timelines” by a North Atlantic Treaty Organization (NATO) Special Operations Combat Medic or higher in order to decrease patient mortality and morbidity. PC utilizes limited resources and is sustained until the patient arrives at an appropriate level of care. Rasmussen TE, Baer DG, Cap AP, et al. 2015. Ahead of the Curve. *J Trauma Acute Care Surg* 79:S61-64.

treatments for moderate, severe and penetrating TBI; acute and chronic pain; regenerative medicine; and, advanced resuscitative care, organ support and critical care solutions. The CCCRP is also interested in the development of sensors; diagnostic and prognostic algorithms; data gathering or capture modalities; processors and autonomous care solutions to improve our capability for remote triage, monitoring, and management of casualties; and products to maintain casualties during prolonged evacuation. Regenerative medicine solutions with potential for early in-theater use will also be considered. In addition, the CCCRP supports research in combined injury that focus on the care of the casualties' conventional injuries in a chemical or biological environment and medical countermeasures to other emerging battlefield threats due to the proliferation of modern weapon systems.

The CCCRP also focuses on the innovations required to reset our wounded Service Members, both in terms of duty performance and quality of life. Innovations developed from CRMRP-supported research efforts are expected to improve restorative treatments and rehabilitative care to maximize function for return to duty (RTD) or civilian life. Medical technologies (drugs, biologics, and devices) and treatment/rehabilitation strategies (methods, guidelines, standards, and information) that will significantly improve the medical care that our wounded Service Members receive within the DOD healthcare system are of particular interest. Implementation of these technologies and strategies should improve the rate of RTD of Service Members, the time to RTD, clinical outcome measures, and quality of life, as well as reduce the hospital stay lengths, clinical workload (patient encounters, treatments, etc.) of caregivers, and initial and long-term costs associated with restorative and rehabilitative or acute care.

The CCCRP supports the conduct of military-relevant clinical research aimed at translating knowledge or materiel from basic and preclinical trauma research into clinical practice. This includes, but is not limited to, single- and multi-center clinical trials performed in the civilian setting to clarify the safety, efficacy, and optimal use of products stemming from the previously mentioned research areas. Comparative effective clinical studies may be encouraged in areas of trauma care where a number of potential known approaches exist and require further investigation to inform selection of the most promising technologies. Novel manufacturing technologies necessary to translate innovative therapies or devices into clinical development are a focus.

The CCCRP supports the conduct of military-relevant, large data research projects, including the use of large databases of common elements from trauma research projects (preclinical, translational, and clinical). Such studies should directly contribute to or effectively enable the data-driven conduct of combat casualty care. Examples include, but are not limited to, post-hoc analysis of data from completed trauma research projects, meta-analyses of a number of otherwise separate but completed studies, and the ability to harmonize data from planned or ongoing but otherwise separate research studies. All projects should adhere to a core set of reporting standards for rigorous study design. The CCCRP strongly encourages award recipients to follow the Animal Research: Reporting In Vivo Experiments (ARRIVE) guidelines 2.0 (<https://doi.org/10.1371/journal.pbio.3000410>). While these standards are written for animal studies, the basic principles of randomization, blinding, sample size estimation, and data handling derive from well-established best practices in clinical studies and should be applied to those projects as well.

Additionally, the CCCRP supports the use of lasers and other light source technology to develop solutions in medicine, photobiology, surgery, and closely related materials sciences, with applications to combat casualty care and other military-specific medical problems.

The Research Areas of Interest to the CCCRP are found in [Appendix I.II](#). *Applicants are urged to read and consider these before preparing their proposals/applications.*

II.A.3. Military Operational Medicine Research Program

The mission of the Military Operational Medicine Research Program (MOMRP) is to protect, optimize, and enhance the readiness and performance of Service Members and their families by developing effective biomedical countermeasures against operational stressors, as well as to prevent and mitigate physical and psychological injuries and threats during training and operations. The MOMRP supports Army Biomedical Performance Enhancement (BPE), Human Dimension, Multi-Domain Operations (MDO), Soldier Lethality, Dense Urban Environment/Subterranean Operations, Army Big 6 Modernization Priorities (see below), and the DOD Total Force Fitness (TFF) concepts.

The MOMRP supports research focused on addressing and delivering actionable solutions across the military lifecycle for critical biomedical problems facing the military today and in the future. Service- and platform-specific issues are addressed through close coordination with all Services to prevent unnecessary duplication of effort.

The highest priorities of the MOMRP are the support of the Army's six modernization priorities:

1. Soldier Lethality³
2. Future Vertical Lift Platforms³
3. Next-Generation Combat Vehicle
4. Army Network
5. Long-Range Precision Fires
6. Air and Missile Defense

The MOMRP is divided into four Research Areas of Interest (with examples of types of research efforts shown in parentheses): (1) *Environmental Health and Protection* (performance optimization and biomarker validation during extreme environmental [heat/cold/altitude] and contaminant/toxicological exposures; validated exposure assessment metrics and tools for critical military environmental chemical threats influencing performance readiness); (2) *Injury Prevention and Reduction* (validated military performance and readiness assessment tools and metrics, physiological mechanisms of musculoskeletal injury, countermeasures against aviation stressors; primary [blast overpressure], secondary [penetrating ballistic fragments or debris], tertiary [accelerative injury], quaternary [burns or exposure to toxic substances], and quinary [illnesses, injuries, or diseases caused by chemical, biological, or radioactive substances] blast

³ The MOMRP supports the Soldier Lethality and Future Vertical Lift Platforms cross-functional teams.

injury mechanisms [auditory and non-auditory], blunt trauma, and accelerative injury prevention strategies; and musculoskeletal injury return-to-duty standards and strategies); (3) *Physiological Health and Performance* (biomedical performance enhancement, performance and recovery nutrition, weight balance optimization, cognitive health and performance sustainment in the face of operational challenges, restorative sleep and fatigue management, resilience to operational and environmental stressors, and the medical aspects of manned-unmanned teaming); and (4) *Psychological Health and Resilience* (post-traumatic stress disorder [PTSD] and other clinical disorders, combat operational stress reactions, suicide prevention and risk reduction, resilience, alcohol and substance misuse prevention, and violence prevention within the military).

More information on these Research Areas of Interest can be found in [Appendix I.III](#).

Applicants are urged to read and consider these before preparing their proposals/applications.

The MOMRP is particularly interested in proposals/applications and products that incorporate integrated biomedical approaches (e.g., systems biology). Proposals/applications are encouraged to leverage existing resources and infrastructure to support lifecycle logistics and sustainability.

Guidance for research studies targeting military families and children: (1) In accordance with Department of Defense Instruction (DoDI) 1402.5 and Army Directive 2014-23, Child Care National Agency Check and Inquiries (CNACI), background investigations are required for all individuals who have regular contact with military dependents under 18 years of age. All individuals who regularly interact with children under 18 years of age in Army-sponsored and -sanctioned programs are required to undergo specific initial background checks and periodic re-verifications. Investigators who propose work involving contact with military dependents under 18 years of age should plan for the additional time and funds required for such investigations. (2) Per Department of Defense Education Activity (DoDEA) Administrative Instruction 2071.3, DoDEA approval is required for research studies involving DoDEA school personnel, school facilities, students, sponsors, and/or data. Investigators proposing to conduct any research activities involving DoDEA schools should plan for the additional time (~3-6 months) and effort required to obtain approval from DoDEA to conduct such activities. Procedures and requirements for the review and approval of a research study request can be found at <https://www.dodea.edu/datacenter/research/requests.cfm>. (3) Per Army Regulation AR 608-18, “The Family Advocacy Program,” The Family Advocacy Research Subcommittee will review, coordinate, and recommend approval and dissemination of all family advocacy research, evaluation projects, and research publications within the Department of the Army.

II.A.4. Medical Biological Defense Research Program

The Defense Threat Reduction Agency (DTRA) Joint Science and Technology Office for Chemical and Biological Defense (JSTO-CBD) manages research directed toward medical biological defense. The DTRA JSTO-CBD has limited funding for proposals/applications submitted through the USAMRDC BAA. DTRA also seeks proposals/applications for its requirements through the Federal Business Opportunities (FedBizOpps) and the DOD Small Business Innovation Research (SBIR) Program solicitations. For information regarding DTRA business opportunities, visit the website at <https://www.dtra.mil/Work-With-Us/Contracts/DTRA-Business-Opportunities/>.

The Medical Biological Defense Research Program (MBDRP) provides medical countermeasures for biological warfare agents. These countermeasures include specialized medical materiel or procedures designed to enhance protection. The priorities of the program are (1) prophylaxis or pretreatment to prevent any casualty; (2) identification and diagnosis of biological agents; and (3) treatment or supportive care regimens. The MBDRP is interested in applications and products incorporating a systems biology approach.

Examples of some of the infectious agents of interest are those causing anthrax, plague, and glanders; the Ebola, Marburg, Venezuelan, Western and Eastern equine encephalitis viruses; and poxvirus models of variola virus. Examples of toxins of interest include those from plants (Ricin) and bacteria (Staphylococcal enterotoxins, botulinum).

The Research Areas of Interest to the MBDRP are found in [Appendix I.IV](#). ***Applicants are urged to read and consider these before preparing their proposals/applications.***

II.A.5. Medical Chemical Defense Research Program

The DTRA JSTO-CBD manages research directed toward medical chemical defense. The DTRA JSTO-CBD has limited funding for proposals/applications submitted through the USAMRDC BAA. DTRA also seeks proposals/applications for its requirements through FedBizOpps and DOD SBIR program solicitations. For information on DTRA business opportunities, visit its website at <https://www.dtra.mil/Work-With-Us/Contracts/DTRA-Business-Opportunities>.

The Medical Chemical Defense Research Program (MCDRP) seeks to preserve combat effectiveness through timely provision of medical countermeasures in response to Joint Service Chemical Warfare Defense Requirements. The fundamental orientation of the program is to protect U.S. Armed Forces from the effects of chemical warfare agents by developing protective, pretreatment, and prophylactic products, providing products usable by the individual Service Member for immediate treatment of chemical warfare agent exposures, developing antidotes/therapeutics to chemical warfare agents, defining care procedures for chemical warfare agent casualties, and advancing management of these casualties. The medical countermeasures are intended to preserve and sustain the Service Members' combat effectiveness in the face of combined threats from chemical and conventional munitions on the integrated battlefield. For combined chemical and conventional injuries that focus on the care of the casualties' conventional injuries in a chemical or biological environment, please refer to CCCRP ([Section II.A.2](#) and [Appendix I.II](#)). The MCDRP is interested in applications and products incorporating a systems biology approach.

The broad goals of this program are described below.

- ***Maintain the technological capability to meet present requirements and counter future chemical warfare agent threats:*** The program will maintain the scientific base and technological capability to develop timely medical countermeasures for both current and future chemical warfare agent threats. Research funded by this program will be used to identify concepts and candidate medical countermeasures for use by the individual Service Member or by medical personnel. Basic and applied research are both supported and may

address topics as diverse as determining sites/mechanisms of action and effects of exposure to chemical warfare agents with emphasis on exploitation of neuroscience technology and respiratory, ocular, and dermal pathophysiology; identifying sites and biochemical mechanisms of action of medical countermeasures; exploiting molecular biological and biotechnological approaches for development of new approaches for medical countermeasures to chemical warfare agents; and exploiting molecular modeling and quantitative structure-activity relationships in support of drug discovery and design.

- ***Provide medical countermeasures for the individual Service Member to maintain combat effectiveness and prevent or reduce injury from chemical warfare agents:*** This goal encompasses research supporting development of new concepts for prophylaxes, pretreatments, antidotes, and therapeutic countermeasures; development of skin protectants and decontaminants; identification of factors that influence safety and efficacy of candidate medical countermeasures; and development and maintenance of preformulation, formulation, and radiolabeling capabilities.
- ***Provide medical management of chemical casualties to enhance survival and expedite the RTD of chemical warfare agent casualties through definitive therapies and life support technologies:*** This goal includes developing concepts and therapeutic regimens and procedures for the management of chemical warfare agent casualties; developing diagnostic and prognostic indicators for chemical warfare agent casualties; developing life-support equipment for definitive care of chemical warfare agent casualties; and addressing the unique challenges of combined injuries due to both physical trauma from kinetic weapons and exposure to chemical agents. When the focus of the research is on the care of the casualties' conventional injuries in a chemical or biological environment, please see the CCCRP ([Section II.A.2](#) and [Appendix I.II](#)).

Recent changes in the security situation facing the United States have not materially reduced the threat that chemical weapons present to the U.S. Armed Forces in the field. Many countries and terrorist groups have the capability of producing and delivering chemical warfare agents, thus posing a substantial and serious threat to the U.S. Armed Forces.

Classical chemical agent threat categories include vesicant or blister agents (e.g., sulfur mustard), blood agents (e.g., cyanide), respiratory agents (e.g., phosgene), and nerve agents (e.g., GA, or Tabun; GB, or Sarin; GD, or Soman; and VX).

The Research Areas of Interest to the MCDRP are found in [Appendix I.V](#). ***Applicants are urged to read and consider these before preparing their proposals/applications.***

II.A.6. Radiation Health Effects Research Program

The Radiation Health Effects Research Program (RHERP) focuses on developing medical countermeasures for acute ionizing radiation injury. The program has interest in the following research focus areas: post-exposure mitigation of radiation injury; protection and prevention of injury from ionizing radiation exposure (prophylaxis); mechanism of radiation injury; and development of novel biodosimetry tools. Research Areas of Interest to the RHERP are found in

[Appendix I.VI](#). The RHERP is interested in applications and products incorporating a systems biology approach.

II.A.7. Other Information

II.A.7.i. Clinical Trial Support

A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Funded trials are required to post a copy of the IRB-approved informed consent form used to enroll subjects on a publicly available federal website in accordance with federal requirements described in 32 CFR 219.

The term “human subjects” is used in this BAA to refer to individuals who will be recruited for or who will participate in the proposed clinical trial. For more information, a Human Subject Resource Document is provided at [Human Subjects Resource Document.pdf \(army.mil\)](#).

If the proposed human subjects research involves the use of a drug that has not been approved by the U.S. Food and Drug Administration (FDA) for the proposed investigational use, then an Investigational New Drug (IND) application to the FDA that meets all requirements under the 21 CFR 312 may be required. *If invited to submit a full proposal/application, the investigator(s) must submit an IND application to the FDA on or before the date of proposal/application submission. If the investigational product is a device, evidence that an Investigational Device Exemption (IDE) application that meets all requirements under 21 CFR 812 has been submitted to the FDA by the application submission deadline, or that the device is exempt or qualifies for an abbreviated IDE, is required.* The government reserves the right to withdraw funding if an IND or IDE is necessary but has not been submitted to the FDA prior to the grant submission deadline, or if documented status of the IND or IDE has not been obtained within 6 months of the award date.

Investigator(s) proposing a clinical trial should refer to [Appendix II](#) for a detailed description of the requirements for such a proposal/application. The pre-proposal/pre-application submission process should be performed as described in [Section II.D.2.a.i](#). Full proposal/application submission is described in [Appendix II, Section B](#). Refer to [Appendix II, Section D](#), the Clinical Trial Submission Checklist, in preparing the full proposal/application.

A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.

II.A.7.ii. Use of Military and Department of Veterans Affairs Populations or Resources

Principal Investigators (PIs) are encouraged to integrate and/or align their research projects with DOD and/or Department of Veterans Affairs (VA) research laboratories and programs and existing clinical trial networks. Collaboration with the DOD or VA is also encouraged. A list of websites that may be useful in identifying additional information about ongoing DOD and VA

areas of research interest or potential opportunities for collaboration can be found in [Appendix III](#).

If the proposed research involves access to active duty military patient populations and/or DOD resources or databases, the PI is responsible for demonstrating such access at the time of proposal/application submission and should develop a plan for maintaining access as needed throughout the proposed research. Access to target active duty military patient population(s) and/or DOD resource(s) or database(s) should be confirmed by including a letter of support, signed by the lowest-ranking person with approval authority. Investigators seeking to conduct research requiring access to government data sources are strongly encouraged to understand access requirements, and when necessary, include a qualified government collaborator. Research proposing access to Military Health System (MHS) data sources (e.g., DOD Trauma Registry, Behavioral Health Data Portal) will require a collaborator who acts as the government sponsor and appropriate data-sharing agreements. Additional information regarding DHA requirements for data-sharing agreements can be found at <https://health.mil/Military-Health-Topics/Privacy-and-Civil-Liberties/Submit-a-Data-Sharing-Application>.

Guidance for research studies targeting DOD personnel for research data collection:

Protocols that target DOD personnel for research data collection may require additional administrative review per DoDI 1100.13. Investigators will need to coordinate with the USAMRDC, Office of Research Protections (ORP), Human Research Protection Office (HRPO), to identify current submission requirements.

Guidance for research studies involving U.S. Army Special Operations Command (USASOC):

Per USASOC policy 24-18, studies involving USASOC Soldiers as human subjects require additional review by the USASOC Research Advisory Committee (RAC) and Human Subjects Research Board (HSRB).

Compensation to DOD-affiliated personnel for participation: Monetary and non-monetary compensation to DOD-affiliated personnel for participation in research while on duty is prohibited with some exceptions. For more details, see DoDI 3216.02, “Protection of Human Subjects and Adherence to Ethical Standards in DOD-Conducted and Supported Research.” You may access a full version of the DoDI by accessing the following link:

<https://www.esd.whs.mil/Portals/54/Documents/DD/issuances/dodi/321602p.pdf>.

Additional information regarding conducting DOD-funded human research with military populations can be found at https://cdmrp.army.mil/pubs/pdf/Conducting%20Research%20Military%20Pop%20DOD_June%202021.pdf.

If the proposed research involves access to VA patient populations, VA study resources and databases, and/or VA research space and equipment, VA PIs must have a plan for obtaining and maintaining access throughout the proposed research. Access to VA patients, resources, and/or VA research space should be confirmed by including a letter of support from the VA Facility Director(s) or an individual designated by the VA Facility Director(s), such as the Associate Chief of Staff for Research and Development (ACOS/R&D) or Clinical Service Chief. If

appropriate, the proposal/application should identify the VA-affiliated non-profit corporation (NPC) as the applicant institution for VA PIs. If the VA NPC is not identified as the applicant institution for administering the funds, the proposal/application should include a letter from the VA ACOS/R&D confirming this arrangement and identifying the institution that will administer the funds associated with the proposed research.

Access to certain DOD or VA patient populations, resources, or databases may only be obtained by collaboration with a DOD or VA investigator who has a substantial role in the research and may not be available to a non-DOD or non-VA investigator if the resource is restricted to DOD or VA personnel. Investigators should be aware of which resources are available to them if the proposed research involves a non-DOD or non-VA investigator collaborating with the DOD and/or VA. If access cannot be confirmed at the time of proposal/application submission, the government reserves the right to withdraw or revoke funding until the PI has demonstrated support for and access to the relevant population(s) and/or resource(s).

Use [Attachment 2: Supporting Documentation](#), to provide relevant documentation to demonstrate access to DOD or VA populations or resources.

II.A.7.iii. Technology Requirements and Standards

Any technology-based research products/prototypes (such as devices, mobile apps, software, IT infrastructure, etc.) that expect to interact with military health IT systems should conform with accepted industry and DOD Information Management/Information Technology (IT) standards for interoperability, cybersecurity, as well as the DOD Architecture Framework (DoDAF) and viewpoints, as follows:

- a. DoDAF and viewpoints
- b. DoDI 8500.01 March, 14, 2014, “Cybersecurity”
- c. DoDI 8510.01 March 12, 2015, “Risk Management Framework (RMF)”
- d. Any products expected to provide data to MHS Genesis, the new DOD Military Electronic Health Record system (which is the military version of Cerner Millennium commercial-off-the-shelf electronic health record), should be aimed toward meeting the Health Level 7 and Fast Healthcare Interoperability Resources standards in order to ultimately provide integration with MHS Genesis.
- e. All software-based research products including computer code, software code, data, and metadata should be provided as deliverables, and electronic versions need to be able to be uploaded to standards-based electronic repositories. Metadata (i.e., the data dictionary and data model) as well as data (i.e., cases) generated in the research should be provided in an industry standard format for access by the government in an open source data repository of electronic deliverables.
- f. OTAs may establish non-standard requirements.

II.A.7.iv. Data Sharing

The USAMRDC intends that information, data, and research resources generated under awards funded by this BAA be made available to the research community and to the public at large. The government reserves the right to identify repositories for submission of data for archive. For additional guidance, refer to the General Submission Instructions, Appendix 2, Section K.

A number of research areas utilize Common Data Elements (CDEs) to facilitate the sharing of data to promote collaboration, accelerate research, and advance knowledge in specific topic areas. In accordance with the White House Office of Science and Technology Policy memorandum, “Increasing Access to the Results of Federally Funded Research,” and Executive Order (EO) 13625 and the National Research Action Plan (NRAP) responding to the EO, “Improving Access to Mental Health Services for Veterans, Service Members, and Families” (August 31, 2012), federally funded research is required to be conducted in a manner that promotes public access to scientific data. In cases of psychological health and TBI, use of CDEs is required under the NRAP. The USAMRDC strongly encourages applicants to incorporate CDE measures appropriate to each field of study, such as:

- PhenX Core and Specialty collections, which are available in the Mental Health Research, Substance Abuse and Addiction, and Research Domains Collections of the PhenX Toolkit (<https://www.phenxtoolkit.org/index.php>) in all studies involving human subjects, as applicable.
- Spinal cord injury research CDEs developed through the collaboration of the International Spinal Cord Society, the American Spinal Injury Association, and the National Institute of Neurological Disorders and Stroke CDE team, as referenced at <https://www.commondataelements.ninds.nih.gov/SCI.aspx>.

TBI research data elements must be reported using the National Institute of Neurological Disorders and Stroke (NINDS) TBI CDEs or entered into the Federal Interagency Traumatic Brain Injury Research (FITBIR) data dictionary as new, unique data elements (UDEs). For the most current version of the NINDS TBI CDEs, go to <http://www.commondataelements.ninds.nih.gov>. Assistance will be available to help the researchers map their study variables to specific CDEs and ensure the formats of the CDEs collected are compatible with the FITBIR Informatics System. Use of the TBI CDEs is required wherever possible in an effort to create standardized definitions and guidelines about the kinds of data to collect and the data collection methods that should be used in clinical studies of TBI. ***Use of UDEs is strongly discouraged and subject to program approval.***

If the project includes the collection of bio-fluids, such as blood, saliva, urine, etc., the PI may be required to include a set of collection variables and patient phenotypic data in order to standardize the quality of bio-fluid studies. The suggested procedures for acquisition, processing, storage, and shipment of bio-fluids can be found in [Appendix IV](#).

OTAs may establish unique data sharing requirements.

II.B. Award Information

II.B.1. Funds Available and Anticipated Number of Awards

The funding amount for this BAA is unspecified, and the number of awards is indeterminate and contingent upon funding availability. Selection of research projects is a highly competitive process and is based on the evaluation of the proposal/application's technical merit, programmatic considerations, and the availability of funds. The quantity of meaningful submissions received normally exceeds the number of awards that the available funding can support. Any funding that is received by the USAMRDC and is appropriate for a research area described within this BAA may be utilized to fund proposals/applications.

II.B.2. Award Amounts and Periods of Performance

There are no specified funding limitations identified for a proposal/application submitted under this BAA. A budget should be commensurate with the nature and complexity of the proposed research. Researchers should submit budgets that include the entire period of performance of the research project. Budgets should include all direct and indirect costs, based on supportable, verifiable estimates. The budget for the full proposal/application should not differ significantly from the Pre-Application Budget Summary Form provided in the pre-proposal/pre-application submission.

Period of performance may differ depending upon the type of funding mechanism awarded under this BAA. For an assistance agreement, the total period of performance may be proposed for up to 4 years in length; additional periods may be considered. For research and development contract awards, the total period of performance may be proposed for up to 5 years in length. For OTAs that utilize the authority within 10 USC 2371 and 2371(b), the period of performance will be dependent upon each specific award made. Because the nature and scope of each proposed research project will vary, it is anticipated that the size and duration of each award will vary. Start dates will vary, depending on when proposals/applications were submitted and reviewed and the negotiation process. However, no proposal/application submitted under this BAA will be considered for funding after 24 months from the date of submission.

Organizations seeking additional or continuation funding must work with their respective PIs to submit new pre-proposals/pre-applications and be invited to submit full proposals/applications.

Refer to the General Submission Instructions, Section III.A.5, for additional information regarding the Research & Related Budget.

II.B.3. Mechanisms of Support

The USAMRDC executes its extramural research program primarily through the awarding of contracts and assistance agreements (grants and cooperative agreements). The type of instrument used to reflect the business relationship between the organization and the government is at the discretion of the government, in accordance with the Federal Grant and Cooperative Agreement Act of 1977, as amended (31 USC 6301-6308), which provides the legal criteria to

select a procurement contract or an assistance agreement. Refer to the General Submission Instructions, Appendix 2, Section D, for additional information.

Proposers awarded a Grant, Cooperative Agreement, Technology Investment Agreement (TIA), or Other Transaction for Research or Prototypes based on their response to this BAA shall follow the applicable rules and regulations governing these various award instruments, but, in all cases, should appropriately identify any potential restrictions on the government's use of any Intellectual Property contemplated under the award instrument in question, refer to [Attachment 8: Data and Research Resource Sharing Plan](#). This includes both noncommercial Items and commercial Items.

II.B.3.a. Procurement Contract

A legal instrument, consistent with 31 USC 6303, which reflects a relationship between the federal government and a state government, local government, or other entity/contractor when the principal purpose of the instrument is to acquire (by purchase, lease, or barter) property or services for the direct benefit or use of the federal government.

Contracts are primarily governed by the following regulations:

- a. FAR
- b. Defense Federal Acquisition Regulation Supplement (DFARS)
- c. Army Federal Acquisition Regulation Supplement (AFARS)

II.B.3.b. Grant

A legal instrument that, consistent with 31 USC 6304, is used to enter into a relationship:

- a. The principal purpose of which is to transfer a thing of value to the recipient to carry out a public purpose of support or stimulation authorized by a law or the United States, rather than to acquire property or services for the federal government's direct benefit or use;
- b. In which substantial involvement is not expected between the federal government and the recipient when carrying out the activity contemplated by the grant; and
- c. No fee or profit is allowed.

II.B.3.c. Cooperative Agreement

A legal instrument which, consistent with 31 USC 6305, is used to enter into the same kind of relationship as a grant (see definition "grant"), except that substantial involvement (collaboration, participation, or intervention in the research) is expected between the federal government and the recipient when carrying out the activity contemplated by the cooperative agreement. The term does not include "cooperative research and development agreements" as defined in 15 USC 3710a. No fee or profit is allowed.

II.B.3.d. Technology Investment Agreement

An assistance instrument as described in 32 CFR Part 37. A TIA may be a cooperative agreement in accordance with 10 USC 2358 with provisions tailored for involving commercial firms or an assistance transaction under 10 USC 2371.

II.B.3.e. Other Transactions for Research

The USAMRDC will also consider the use of Other Transactions for Research as a vehicle for award under this BAA. In accordance with 10 USC 2371, “Research projects: transactions other than contracts and grants,” such other transactions shall not be entered into unless the following conditions are satisfied:

1. To the maximum extent practicable, no other transaction entered into shall provide for research that duplicates research being conducted under existing programs carried out by DOD.
2. The funds provided by the government under an other transaction authorized shall not exceed, to the extent that the Secretary of Defense determines practicable, the total amount provided by other parties to the other transaction.
3. An Other Transaction for Research may only be used for a research project when the use of a standard contract, grant, or cooperative agreement for such project is not feasible or appropriate.

II.B.3.f. Other Transactions for Prototypes

The USAMRDC will also consider the use of Other Transactions for Prototypes as a vehicle for award under this BAA. In accordance with 10 USC 2371b, Prototype projects; transactions other than contracts and grants: “No official of an agency shall enter into a transaction (other than a contract, grant, or cooperative agreement) for a prototype project under the authority of 10 USC 2371b unless one of the following conditions is met:

- (A) There is at least one nontraditional defense contractor or nonprofit research institution participating to a significant extent in the prototype project.
- (B) All significant participants in the transaction other than the Federal Government are small businesses (including small businesses participating in a program described under section 9 of the Small Business Act (15 U.S.C. 638)) or nontraditional defense contractors.
- (C) At least one third of the total cost of the prototype project is to be paid out of funds provided by sources other than the Federal Government.
- (D) The senior procurement executive for the agency determines in writing that exceptional circumstances justify the use of a transaction that provides for innovative business arrangements or structures that would not be feasible or appropriate under a contract, or would provide an opportunity to expand the defense supply base in a manner that would not be practical or feasible under a contract.”

In accordance with 10 USC 2371b(f), the government may award a follow-on production contract or other transaction for any other transaction awarded under this BAA if: (1) that participant in the other transaction, or a recognized successor in interest to the other transaction, successfully completed the entire prototype project provided for in the other transaction, as modified; and (2) the other transaction provides for the award of a follow-on production contract or other transaction to the participant, or a recognized successor in interest to the other transaction.

Additional information can be found in the most current version of the Other Transactions Guide for Prototype Projects at <https://www.acq.osd.mil/dpap/cpic/cp/10USC2371bOTs.html>.

II.C. Eligibility Information

II.C.1. Eligible Applicants

II.C.1.a. Organizations

Awards are made to eligible organizations, not to individuals. Organizations eligible to apply include national, international, for-profit, non-profit, public, and private organizations. Refer to the General Submission Instructions, Appendix 3, Section B, for general eligibility information.

NOTE: In accordance with FAR 35.017, Federally Funded Research and Development Centers (FFRDCs) are not eligible to directly receive awards under this BAA. However, teaming arrangements between FFRDCs and eligible organizations are allowed so long as they are permitted under the sponsoring agreement between the federal government and the specific FFRDC.

The USAMRDC is committed to supporting small businesses. Small business, Veteran-owned small business, Service-disabled Veteran-owned small business, HUBZone small business, small disadvantaged business, and woman-owned small business concerns will be given the maximum practical opportunity to participate through subawards on research proposals/applications submitted through this BAA.

Government Agencies Within the United States: Local, state, and federal government agencies are eligible to the extent that proposals/applications do not overlap with their fully funded internal programs. Such agencies are required to explain how their proposals/applications do not overlap with their internal programs.

II.C.1.b. Investigator(s)

Eligible investigators include all individuals, regardless of ethnicity, nationality, or citizenship status, who are employed by or affiliated with an eligible organization.

Investigators are cautioned that awards are made to organizations only, not individuals.

II.C.2. Cost Sharing

Generally, there is no requirement for cost sharing, matching, or cost participation to be eligible for award under this BAA. Cost sharing and matching is not an evaluation factor used under this BAA. Exceptions may exist if the applicant is proposing the use of a TIA, Research OTA, or Prototype OTA as an award instrument. Cost-sharing requirements may be found at 32 CFR 37 for TIAs. Cost-sharing requirements for OTAs are stated in 10 USC 2371 for Research OTAs and 10 USC 2371b for Prototype OTAs.

In addition, if cost sharing is proposed on a grant or cooperative agreement proposal/application submitted by a nonprofit or institution of higher education, the award will be subject to the restrictions at 2 CFR 200.306. If cost sharing is proposed on a contract proposal/application, the award will be subject to the restrictions at FAR 35.003.

II.C.3. Other

Organizations must be able to access .gov and .mil websites in order to fulfill the financial and technical deliverable requirements of the award and submit invoices for payment.

Use of the System for Award Management (SAM) and the Federal Awardee Performance and Integrity Information System (FAPIIS): To protect the public interest, the federal government ensures the integrity of federal programs by striving to conduct business only with responsible organizations. The USAMRDC uses the “Exclusions” within the Performance Information functional area of the SAM and data from FAPIIS, a component within SAM, to verify that an organization is eligible to receive federal awards. More information about SAM and FAPIIS is available at <https://sam.gov/>. Refer to the General Submission Instructions, Appendix 3, for additional information.

Conflicts of Interest: All awards must be free of conflicts of interest (COIs) that could bias the research results. Prior to award of a contract, grant, or agreement, applicants will be required to disclose all potential or actual COIs along with a plan to manage them. An award may not be made if it is determined by the Contracting, Grants, or Agreements Officer that COIs cannot be adequately managed. Refer to the General Submission Instructions, Appendix 3, for additional information.

Review of Risk: The following areas may be reviewed in evaluating the risk posed by an applicant: financial stability; quality of management systems and operational controls; history of performance; reports and findings from audits; ability to effectively implement statutory, regulatory, or other requirements imposed on non-federal entities; degree of institutional support; integrity; adequacy of facilities; and conformance with safety and environmental statutes and regulations.

Subcontracting Plan: If the resultant award is a contract that exceeds \$700,000 and the offeror is other than a small business, the contractor will be required to submit a subcontracting plan for small business and small disadvantaged business concerns, in accordance with FAR 19.702. The subcontracting plan will have to comply with the requirements in FAR 19.704. A mutually agreeable plan will be incorporated as part of the resultant contract. This requirement is not applicable to OTAs.

II.D. Proposal/Application Submission Information

II.D.1. Where to Obtain the Proposal/Application Submission Package

To obtain the complete Grants.gov proposal/application package (hereinafter, submission package), including all required forms, perform a Grants.gov (<https://www.grants.gov/>) basic search using the Funding Opportunity Number **W81XWH18SBAA1**.

Submission is a two-step process requiring both (1) pre-proposal/pre-application submission through eBRAP (<https://eBRAP.org/>) and (2) full proposal/application submission through Grants.gov (<https://www.grants.gov/>).

II.D.2. Content and Form of Proposal/Application Submission for Research Awards Not Including a Clinical Trial

NOTE: Investigator(s) proposing a clinical trial should refer to [Appendix II](#) for a detailed description of the requirements for such a proposal/application.

Pre-Proposal/Pre-Application Submission: Submission of a pre-proposal/pre-application is required and must be submitted through eBRAP (<https://eBRAP.org/>). If the USAMRDC is interested in receiving a full proposal/application, the PI will be sent an invitation via eBRAP to submit. eBRAP is a multifunctional web-based system that allows PIs to submit their pre-proposals/pre-applications electronically through a secure connection, to view and edit the content of their pre-proposals/pre-applications and full proposals/applications, to receive communications, and to submit documentation during award negotiations and period of performance.

A key feature of eBRAP is the ability of an organization's representatives and PIs to view and modify the full proposal/application submissions associated with them. eBRAP will validate full proposal/application files against the BAA requirements, and discrepancies will be noted in an email to the PI and in the Full Application Files tab in eBRAP. It is the applicant's responsibility to review all proposal/application components for accuracy as well as ensure proper sequence as specified in this BAA.

The proposal/application title, eBRAP log number, and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-proposal/pre-application and proposal/application submission process. Inconsistencies may delay proposal/application processing and limit or negate the ability to view, modify, and verify the proposal/application in eBRAP. If any changes need to be made, the applicant should contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507 prior to the proposal/application deadline.

The organization, Business Official, and PI must register in eBRAP before submitting a pre-proposal/pre-application. Upon completion of an organization's registration in eBRAP and approval by the eBRAP Help Desk, the organization name will be displayed in eBRAP to assist the organization's Business Officials and PIs as they register. The organization, Business

Officials, and PIs must all be registered and affiliated in eBRAP. (See *eBRAP User Guide* at <https://ebrap.org/eBRAP/public/UserGuide.pdf>.)

Pre-proposals/pre-applications may be submitted at any time prior to the BAA closing date. Pre-proposals/pre-applications should describe specific ideas or projects that pertain to any of the areas described under “Program Description” in this BAA. A pre-proposal/pre-application must include a brief description of the scientific methods and design to address the problem as described below. Brochures or other descriptions of general organizational or individual capabilities will not be accepted as a pre-proposal/pre-application. ***DO NOT include any proprietary information in the pre-proposal/pre-application.***

II.D.2.a.i. Step 1: Pre-Proposal/Pre-Application Submission Content

During the pre-proposal/pre-application process, each submission is assigned a unique log number by eBRAP. This unique eBRAP log number will be needed during the full proposal/application submission process.

All pre-proposal/pre-application components must be submitted through eBRAP (<https://eBRAP.org>). Because the invitation to submit a proposal/application is based on the contents of the pre-proposal/pre-application, investigators should not change the title or research objectives after the pre-proposal/pre-application is submitted.

PIs and organizations identified in the pre-proposal/pre-application should be the same as those intended for the subsequent proposal/application submission. If any changes are necessary after submission of the pre-proposal/pre-application, the PI must contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507. A change in PI or organization after submission of the pre-proposal/pre-application will be allowed only at the discretion of the USAMRAA Contracting, Agreements, or Grants Officer.

The pre-proposal/pre-application consists of the following components, which are organized in eBRAP by separate tabs for each proposal/application type. Select “Research,” “Research Including Clinical Trial,” or “Conference/Symposium” when initiating the proposal/application. Refer to the General Submission Instructions, Section II, for additional information on pre-proposal/pre-application submission.

- **Tab 1 – Application Information**

Enter the information as described in eBRAP before continuing the pre-proposal/pre-application. Submission of proposal/application information includes assignment of primary and secondary research classification codes, which may be found at <https://ebrap.org/eBRAP/public/Program.htm>. Note that the codes have been recently revised. Applicants are strongly encouraged to review and confirm the codes prior to making their selection.

- **Tab 2 – Application Contact**

Enter contact information for the PI. Enter the organization’s Business Official responsible for the sponsored program administration (the “person to be contacted on matters involving

this application” in Block 5 of the Grants.gov SF424 [Research & Related (R&R)]. The Business Official must either be selected from the eBRAP list or invited for the pre-proposal/pre-application to be submitted.

Select the performing organization (site at which the PI will perform the proposed work) and the contracting organization (organization submitting on behalf of the PI, which corresponds to Block 5 on the Grants.gov SF424 [R&R]), and click on “Add Organizations to this Pre-application.” The organization(s) must be either selected from the eBRAP drop-down list or be invited in order for the pre-proposal/pre-application to be submitted.

It is recommended that PIs identify an Alternate Submitter in the event that assistance with pre-proposal/pre-application submission is needed.

- **Tab 3 – Collaborators and Key Personnel**

Enter the name, organization, and role of all collaborators and key personnel associated with the pre-proposal/pre-application.

- **Tab 4 – Conflicts of Interest**

List all individuals other than collaborators and key personnel who may have a COI in the review of the pre-proposal/pre-application (including those with whom the PI has a personal or professional relationship).

- **Tab 5 – Required Files**

NOTE: No figures, charts, graphs, or other additional material will be accepted during the pre-proposal/pre-application process.

Provide responses in the appropriate data fields for the following in eBRAP. **EVERY DATA FIELD MUST CONTAIN COMPLETE INFORMATION.** eBRAP will truncate characters exceeding the limit specified for each data field. Enter “none” if there is no information to be included.

- Problem To Be Studied (4,000 character limit, including spaces).
- Theoretical Rationale, Scientific Methods, and Design (4,000 character limit, including spaces).
- Significance and/or Uniqueness of the Proposed Effort (4,000 character limit, including spaces).
- Military Relevance and Impact (4,000 character limit, including spaces).
- Brief Description of Research Involving Animals, Human Anatomical Substances and/or Human Subjects (4,000 character limit, including spaces).

- Plans and Strategy for Translation, Implementation, and/or Commercialization (4,000 character limit, including spaces).

Upload document(s) as individual PDF file(s). eBRAP will not allow a document to be uploaded in the Required Files tab if the number of pages exceeds the limits specified below.

- Budget Summary: Upload as “BudgetSummary.pdf”. Complete the two-page Budget Summary Form (available for download in eBRAP) as instructed.
- PI and Key Personnel Biographical Sketches (five-page limit per individual): Use boldfaced type or highlight titles of publications relevant to the proposed project. All biographical sketches should be uploaded as a single combined file.

Refer to the General Submission Instructions, Section II.C, for detailed information.

- **Tab 6 – Submit Pre-Application**

This tab must be completed for the pre-proposal/pre-application to be accepted and processed.

Pre-Proposal/Pre-Application Screening

USAMRDC scientists or outside experts will screen pre-proposals/pre-applications for technical merit and programmatic considerations. Based on the screening of the pre-proposal/pre-application, a PI may be invited to submit a full proposal/application.

Notification of Pre-Proposal/Pre-Application Screening Results

Following the pre-proposal/pre-application screening, PIs will be notified as to whether or not they are invited to submit full proposals/applications; however, they will not receive feedback (e.g., a critique of strengths and weaknesses) on their pre-proposals/pre-applications. Within 120 calendar days of submission, PIs should receive email notification via eBRAP regarding disposition of their pre-proposals/pre-applications.

II.D.2.a.ii. Step 2: Full Proposal/Application Submission Content

Proposals/applications will not be accepted unless the PI has received notification of invitation.

No allowances/exceptions to deadlines will be made for submission problems encountered by the applicant organization using system-to-system interfaces with Grants.gov.

Each proposal/application submission must include the completed full submission package for this BAA. The full submission package is submitted by the Authorized Organizational Representative through Grants.gov (<https://www.grants.gov/>).

II.D.2.a.iii. Full Proposal/Application Submission Guidelines

Applicants must create a Grants.gov Workspace for submission, which allows the proposal/application components to be completed online and routed through the applicant organization for review prior to submission. Applicants may choose to download and save individual PDF forms rather than filling out webforms in the Workspace. A compatible version of Adobe Reader **must** be used to view, complete, and submit a proposal/application package consisting of PDF forms. If more than one person is entering text into a proposal/application package, the **same version** of Adobe Reader software should be used by each person. Check the version number of the Adobe software on each user's computer to make sure the versions match. Using different versions of Adobe Reader may cause submission and/or save errors – even if each version is individually compatible with Grants.gov. Refer to the General Submission Instructions, Section III, and the “Apply For Grants” page of Grants.gov (<https://www.grants.gov/web/grants/applicants/apply-for-grants.html>) for further information about the Grants.gov Workspace submission process.

To submit the proposal/application package, create a Grants.gov Workspace. Add participants (investigators and Business Officials) to the Workspace, complete all required forms, and check for errors before submission. A proposal/application may be submitted through Workspace by clicking the “Sign and Submit” button on the “Manage Workspace” page, under the “Forms” tab. Grants.gov recommends submission of the proposal/application package **at least 24-48 hours prior to the BAA closing date** to allow time to correct any potential technical issues that may disrupt the proposal/application submission.

NOTE: If either the Project Narrative or the budget fails eBRAP validation or if the Project Narrative or the budget needs to be modified, an updated Grants.gov application package must be submitted via Grants.gov as a “Changed/Corrected Application” with the previous Grants.gov Tracking ID prior to the proposal/application submission deadline.

Proprietary information should only be included if necessary for evaluation of the proposal/application. Conspicuously and legibly mark any proprietary information that is included in the proposal/application.

The full proposal/application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the 5-day proposal/application verification period. During the proposal/application verification period, the full application package, **with the exception of the Project Narrative and Budget Form**, may be modified.

The organization's Business Official or Authorized Organizational Representative (or Resource Manager/Comptroller) should approve/verify the full proposal/application submission prior to the end of the 5-day proposal/application verification period.

After successfully submitting a Workspace package, a Grants.gov Tracking Number is automatically assigned to the package. The number will be listed on the “Confirmation” page that is generated after submission. Refer to the General Submission Instructions, Section III, for further information regarding Grants.gov requirements.

II.D.2.a.iv. Full Proposal/Application Submission Components

The Grants.gov Workspace submission package includes the following components (refer to the General Submission Instructions, Section III, for additional information on proposal/application submission). Note that components for a proposal/application including a clinical trial are provided in [Appendix II](#).

- **SF424 (R&R) Application for Federal Assistance Form:** Refer to the General Submission Instructions, Section III.A.1, for detailed information.

Attachments

Each attachment to the full proposal/application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines listed in the General Submission Instructions, Appendix 4.

For all attachments, ensure that the file names are consistent with the guidance. Attachments will be rejected if the file names are longer than 50 characters or if they have incorrect file names, i.e., containing characters other than the following: A-Z, a-z, 0-9, underscore, hyphen, space, and period. In addition, there are file size limits that may apply in some circumstances. Individual attachments may not exceed 20 MB and the file size for the entire full submission package may not exceed 200 MB.

- **Attachment 1: Project Narrative (15-page limit): Upload as “ProjectNarrative.pdf”.** There is no form for this information. The attachments must be PDF files in accordance with the formatting guidelines specified for full proposal/application preparation. The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the proposal/application.

A detailed innovative/state of the art description of the research to be undertaken should be submitted. This should include the areas provided below and address their relationship to the state of knowledge in the field and to comparable work in progress elsewhere. Evaluation of the proposed research will be influenced by the adequacy of this information.

Literature references and curriculum vitae will be shown in separate addenda entries. The following general outline should be followed:

- **Background:** Provide a brief statement of ideas and theoretical reasoning behind the proposed study. Describe previous experience most pertinent to this proposal/application. Cite relevant literature references. Include discussion of any findings (if available) from relevant pilot or preliminary work or any related work underway. For development of devices and technologies, provide an intellectual property plan as part of the [supporting documentation](#).

- Hypothesis: State the hypothesis to be tested and the expected results. For development of devices and technologies, discuss the technical feasibility of the proposed project including historical background of the problem, previous and current solutions, similar projects previously undertaken, and related development activities.
- Technical Objectives: State concisely the question to be answered by each research objective.
- Project Milestones: Identify timelines for critical events that must be accomplished in order for the project to be successful in terms of cost, schedule, and performance. For development of devices and technologies, discuss the timelines and provide a commercialization strategy/plan for the technology being developed.
- Military Significance: State precisely the estimates as to the immediate and/or long-range usefulness of this study to the U.S. Armed Forces, as distinguished from general advancement of knowledge in medicine.
- Public Purpose: If appropriate, provide a concise, detailed description of how this research project will benefit the general public.
- Methods: Give details about the experimental design and methodology. If the methodology is new or unusual, describe it in sufficient detail for evaluation. For synthetic chemistry applications, include a clear statement of the rationale for the proposed syntheses. Outline and document the routes to the syntheses. For development of devices and technologies, discuss the engineering/technical design to achieve the project goals demonstrating the feasibility of the proposed product development. Discuss the perceived engineering/design strengths and flaws and recommendations for overcoming/preventing them. For clinical research studies involving human subjects, describe the recruitment plan to include relevant support and justification for sample size, study inclusion criteria, and data collection instruments, as well as access to populations. The proposal/application should describe a plan for data access and sharing. (Access to subjects and data is the sole responsibility of the investigator.) As relevant, describe plans for addressing issues unique to working with military populations. For studies involving human and animal research, provide a statistical and data analysis plan. Include a complete power analysis to demonstrate that the sample size is appropriate to meet the objectives of the study. Describe the statistical model and data analysis plan with respect to the study objectives as appropriate to the type of study. For clinical studies and applied research involving human subjects, specify the approximate number of human subjects that will be enrolled. If multiple study sites are involved, state the approximate number to be enrolled at each site. When possible, investigators should write protocols for research with human subjects and/or human anatomical substances that are specific to the DOD-supported effort outlined in the submitted proposal/application. The research protocol submitted for HRPO review MUST only include those activities funded by the DOD, as referenced in the Statement of Work

(SOW). The HRPO will NOT review protocols submitted for DOD-funded activities if such studies have been added to an ongoing/existing protocol.

- Additional Information: If human subjects, animals, or cadavers are involved in the research, proposals/applications may be submitted prior to obtaining human, animal, or cadaver protocol institutional approvals. However, protocols with required institutional approvals must be submitted no later than 60 days after award to demonstrate continued progress and ensure continuation of payment. The Contracting, Agreements, or Grants Officer may make exceptions in situations where human and/or animal use is not expected to begin until after the first year of the research project. In such cases, a timeframe for submission of the appropriate protocols and institutional approvals will be established prior to award.

PIs and collaborating organizations may not use, employ, or subcontract for the use of any human participants, including the use of human anatomical substances, human data, and/or human cadavers, or laboratory animals until applicable regulatory documents are reviewed and approved by the USAMRDC ORP to ensure that DOD regulations have been met.

- For studies with prospective accrual of human subjects, indicate quarterly enrollment targets. For clinical research, see Attachment 9, Human Subject Recruitment and Safety Procedures for the required strategy for the inclusion of women and minorities appropriate to the objectives of the study.
- For use of human anatomical substances, identify the commercial or organizational source(s) of the material. For cell lines, identify cell line(s) to be used. If human anatomical substances (including cell lines) will be used, specify whether or not identifiable information is accessible to the research team by any means.
- If applicable, indicate time required for submission and/or approval of documents (e.g., IND and IDE) to the FDA or appropriate government regulatory agency.
- For studies involving human subjects, allow at least 2 to 3 months for regulatory review and approval by the USAMRDC HRPO; this does not include the additional time required for local Institutional Review Board (IRB) review and approval, as stated above.
- For animal studies, allow at least 3 to 4 months for regulatory review and approval by the USAMRDC Animal Care and Use Review Office; this does not include the additional time required for local Institutional Animal Care and Use Committee review and approval, as stated above.
- Refer to the General Submission Instructions, Appendix 1, for additional regulatory information.
- **Attachment 2: Supporting Documentation:** The attachment should be in PDF in accordance with the formatting guidelines specified for full proposal/application preparation. Start each document on a new page. **Combine and upload as a single file**

named “Support.pdf”. If documents are scanned to pdf, the lowest resolution (100 to 150 dpi) should be used. *There are no page limits for any of these components unless otherwise noted.*

- Bibliography and References Cited: List the references in the order they appear in the proposal/application narrative. Use a reference format that gives the title of the citation. Do not send or attach copies of articles in print. There is no form for this information.
- List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols.
- Facilities, Existing Equipment, and Other Resources: Describe the facilities and existing equipment available for performance of the proposed research project and any additional resources proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present government award under which the facilities or equipment are now accountable. There is no form for this information.
- Publications and/or Patent Abstracts (five-document limit): Include relevant publication URLs and/or patent abstracts. If articles are not publicly available, then a copy/copies of the published manuscript(s) must be attached.
- Letters of Organizational Support: Provide a letter (or letters, if applicable), signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project. A letter from each organization involved in the project should be provided.
- Letters of Collaboration (if applicable): Provide letter(s) supporting stated collaborative efforts necessary for the project’s success, even if the collaboration is offered at no cost. If an investigator at an intramural organization is named as a collaborator on a proposal/application submitted through an extramural organization, the proposal/application must include a letter from the collaborator’s Commander or Commanding Officer at the intramural organization that authorizes the collaborator’s involvement.
- Use of DOD Resources (if applicable): Provide a letter of support signed by the lowest-ranking person with approval authority confirming access to active duty military populations and/or DOD resources or databases.
- Use of VA Resources (if applicable): Provide a letter of support from the VA Facility Director(s) or individual designated by the VA Facility Director(s), such as the ACOS/R&D or Clinical Service Chief confirming access to VA patients, resources, and/or VA research space. For VA PIs, if the VA NPC is not identified as the applicant institution for administering the funds, include a letter from the VA ACOS/R&D confirming this arrangement and identifying the institution that will administer the funds associated with the proposed research.

- *If the project involves collaboration with a Military Facility, special requirements apply.* A DOD researcher, to include collaborating DOD PIs, must obtain a letter from his/her commanding officer or Military Facility Director authorizing his/her participation in the research project. This letter must be included with the proposal/application.
- Joint Sponsorship: Describe present or prospective joint sponsorship of any portion of the program outlined in the proposal/application. In the absence of agreements between/among sponsors for joint support, the proposal/application should be structured so that the research can be carried out without the resources of any other sponsor. If, however, it is desirable to request partial support from another agency, the proposed plan should be stated and the reasons documented. If the plan cannot be formulated at the time the proposal/application is submitted, information should be sent later as an addendum to the proposal/application. Prior approval from both/all agencies must be secured for research to be undertaken under joint sponsorship. Provide letters of support related to recruitment, subject access, and data access plans.
- Intellectual Property (if applicable):
 - Background and Proprietary Information: All software and data first produced under the award are subject to a federal purpose license. A term of the award requires the recipient to grant the government all necessary and appropriate licenses, which could include licenses to background and proprietary information that have been developed at private expense.

Therefore, it is important to disclose/list any intellectual property (software, data, patents, etc.) that will be used in performance of the project or provide a statement that none will be used. If applicable, all proprietary information to be provided to the government should be stated and identified; the applicant should indicate whether a waiver of the federal purpose license will be required.

- Intellectual and Material Property Plan: Provide a plan for resolving intellectual and material property issues among participating organizations.
- **Attachment 3: Technical Abstract (one-page limit): Upload as “TechAbs.pdf”.** The abstract is vitally important to both the scientific peer and programmatic review processes. In accordance with Section 8123 of the Consolidated and Further Continuing Appropriations Act, 2015 (Public Law 113-235), the PI is required to submit a technical abstract that fully describes the proposed work. The abstract must contain the title of the project and the name of the PI. Do not include figures or tables in the abstract. Use only characters available on a standard QWERTY keyboard. Spell out all Greek or other non-English letters. Abstracts of all funded research projects will be posted publicly. ***Do not include proprietary or confidential information.***

The structured technical abstract should be clear and concise and, at a minimum, provide the following information:

- Background: Provide a brief statement of the ideas and theoretical reasoning behind the proposed work.
 - Objective/Hypothesis: State the objective/hypothesis to be tested. Provide evidence or rationale that supports the objective/hypothesis.
 - Specific Aims: State concisely the specific aims of the study.
 - Study Design: Briefly describe the study design.
 - Relevance: Provide a brief statement explaining the potential relevance of the proposed work to the specific topic area being addressed and its impact on health outcomes.
- **Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf”.** The lay abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. ***Do not include proprietary or confidential information.*** Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

Lay abstracts should be written using the outline below. Do not duplicate the technical abstract.

- Clearly describe the objectives and theoretical reasoning behind the proposed work in a manner readily understood by readers without a background in science or medicine.
 - Clearly describe the problem or question to be addressed and the ultimate applicability and impact of the research.
 - What types of patients will it help and how will it help them? Include the current available statistics to the related injury/condition.
 - What are the potential clinical applications, benefits, and risks?
 - What is the projected timeline it may take to achieve the expected patient-related outcome?
 - Describe how the proposed project will benefit Service Members, Veterans, and/or their family members.
- **Attachment 5: Statement of Work (two-page limit): Upload as “SOW.pdf”.** The SOW outlines and establishes the performance expectations and milestones for which the USAMRDC may provide funding. The SOW will be incorporated into the award document and, as such, is subject to release under the Freedom of Information Act. The SOW should identify all collaborating research sites involved in the performance of the research. Suggested SOW formats and examples specific to different types of research projects are available on the eBRAP “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>).

A series of relatively short statements should be included that comprise the approach to each of the major goals or objectives of the proposed research. The statements should outline the specific tasks, systems, key assessments/techniques, and materials that are reasonable estimates for testing the proposed hypotheses of the study. A timeline should be included that shows the work statements to be accomplished in each year of the award. Any animal use and/or human subjects recruitment should be included. Allow at least 2 to 3 months for the USAMRDC ORP regulatory review and approval processes for studies involving human subjects and 2 to 3 months for studies involving animal subjects.

- **Attachment 6: Impact/Outcomes Statement (one-page limit): Upload as “Impact.pdf”.** Explain the potential impact of the research in the field, the significance of this impact, and when it can be anticipated. Explain how the results of this research are expected to impact the intended beneficiaries. Expand upon the dual (military and public) purpose for the research, as appropriate.
- **Attachment 7: Military Relevance Statement (one-page limit): Upload as “MilRel.pdf”.**
 - Describe how the proposed study is responsive to the healthcare needs of military Service Members, Veterans, and/or beneficiaries. Provide information about the incidence and/or prevalence of the disease or condition in the general population as well as in military Service Members, Veterans, and/or beneficiaries.
 - If active duty military, military families, and/or Veteran population(s) will be used in the proposed research project, describe the population(s) and the appropriateness of the population(s) for the proposed study. If a non-military population will be used for the proposed research project, explain how the population simulates the targeted population (i.e., military Service Members, Veterans, and/or beneficiaries).
 - As applicable, show how the proposed research project aligns with DOD and VA areas of research interests. Provide a description of how the knowledge or technology gained from the research could be implemented in a dual-use capacity to benefit the civilian population and address a military need, as appropriate.
- **Attachment 8: Data and Research Resource Sharing Plan (one-page limit): *All data must be shared while ensuring appropriate protection of information.* Upload as “Sharing.pdf”.** Describe how unique and/or final research data will be shared with the research community, along with any resulting research resources. This includes cases where pre-existing data or research resources will be utilized and/or modified during the course of the proposed project. If there are limitations associated with a pre-existing agreement for the original data or research resources that preclude subsequent sharing, the applicant should explain this in the data and/or research resource sharing plan. For projects involving clinical trials, PIs may be required to register their clinical trials on Clinicaltrials.gov (<https://clinicaltrials.gov/>). For projects involving TBI, PIs may be required to report data to the FITBIR informatics system (<https://fitbir.nih.gov/>). If the project includes systems biology-related research, the PI is encouraged to make the systems biology data, generated via an award, available to the research community by

depositing research data into the SysBioCube system (<https://sysbiocube-abcc.ncifcrf.gov>). For studies that will enroll subjects with psychological health disorders, awardees may be requested to submit data to the National Institute of Mental Health Data Archive (NDA) <https://data-archive.nimh.nih.gov>. The NDA is a data repository run by the National Institute of Mental Health (NIMH) that allows researchers studying mental illness to collect and share de-identified information with each other. Such studies may require the inclusion of specific language in the informed consent form which references the NDA (see [Appendix V](#)).

Refer to the General Submission Instructions, Appendix 2, Section K, for additional information.

- **Attachment 9: Post-Award Transition Plan (two-page limit): Upload as “Transition.pdf”.** Describe the methods and strategies proposed to move the anticipated research outcomes to the next phase of development or clinical application (clinical trials, commercialization, and/or delivery to the civilian or military market) after successful completion of the award. Applicants are encouraged to work with their organization’s Technology Transfer Office (or equivalent) to develop the transition plan. Applicants are encouraged to explore developing relationships with industry and/or other funding agencies to facilitate moving the product into the next phase of development. The post-award transition plan should include the components listed below:
 - The project’s anticipated research outcomes including knowledge products, clinical products for development, etc.
 - Using [Appendix VI](#) as a guide, describe the maturity of the product and provide the current and projected research technology or knowledge readiness level (as appropriate) at the end of the proposed project or knowledge outcome.
 - A description of the scientific or technical requirements needed to advance the research findings. Include steps necessary for FDA regulatory approval for the planning indication, and compliance with Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP), and Good Clinical Practice (GCP) guidelines as appropriate.
 - A timeline with defined milestones and deliverables describing the expected post-award progress of the results toward the next phase of development and eventual clinical impact.
 - An assessment of the opportunities available and potential barriers that would impact the progress of commercializing and/or translating the study results into clinical practice.
 - A plan for management of intellectual property.
 - Details of the funding strategy to transition to the next level of investigation, development, and/or commercialization (e.g., partners, internal/external funding opportunities to be applied for).

- A description of collaborations and other resources that will be used to provide continuity of development.
- A plan to distribute the findings or intervention to the civilian and/or military communities.
- **Attachment 10: Human Subject Recruitment and Safety Procedures (no page limit), if applicable; required for all studies recruiting human subjects: Upload as “HumSubProc.pdf”.** The Human Subject Recruitment and Safety Procedures attachment should include the components listed below.
 - **Study Population:** Describe the target population (to whom the study findings will be generalized) and the nature, approximate number, and pertinent demographic characteristics of the accessible population at the study site(s) (population from whom the sample will be recruited/drawn). Provide a table of anticipated enrollment counts at each study site. Demonstrate that the research team has access to the proposed study population at each site, and describe the efforts that will be made to achieve accrual goals. Furthermore, discuss past efforts in recruiting human subjects from the target population for previous clinical trials (if applicable). Address any potential barriers to accrual and plans for addressing unanticipated delays, including a mitigation plan for slow or low enrollment or poor retention. Identify ongoing clinical studies that may compete for the same patient population and how they may impact enrollment progress. Provide justification related to the scientific goals of the proposed study for limiting inclusion of any group by age, race, ethnicity, or sex/gender.
 - **Inclusion/Exclusion Criteria:** List the inclusion and exclusion criteria for the proposed clinical study. Inclusion/exclusion criteria should take into consideration the specific risk profile of the studies to be conducted and the standard of care for that patient population. Provide detailed justification for exclusions.
 - ***Inclusion of Women and Minorities in Study:*** Consistent with the Belmont Report, “Ethical Principles and Guidelines for the Protection of Human Subjects,” and congressional legislation, special attention is given to inclusion of women and/or minorities in studies funded or supported by the USAMRDC. This policy is intended to promote equity both in assuming the burdens and in receiving the benefits of human subjects research. Describe the strategy for the inclusion of women and minorities in the clinical trial appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex/gender, race, and ethnicity, and an accompanying rationale for the selection of subjects. Provide an anticipated enrollment table(s) with the proposed enrollment distributed on the basis of sex/gender, race, and ethnicity. The Suggested Inclusion Enrollment Report Format, Policy on Inclusion of Women and Minorities, and Frequently Asked Questions for the policy may be downloaded from eBRAP at <https://ebrap.org/eBRAP/public/Program.htm>.

- **Description of the Recruitment Process:** Explain methods for identification of potential human subjects (e.g., medical record review, obtaining sampling lists, healthcare provider identification).
 - Describe the recruitment process in detail. Address who will identify potential human subjects, who will recruit them, and what methods will be used to recruit them.
 - If human subjects will be compensated for participation in the study, include a detailed description of and justification for the compensation plan.
 - Describe the recruitment and advertisement materials. The recruitment materials should not be coercive or offer undue inducements and should accurately reflect the study.

- **Description of the Informed Consent Process:** Specifically describe the plan for obtaining informed consent from human subjects.
 - *For the proposed clinical study, provide a draft, in English, of the Informed Consent Form.*
 - Identify who is responsible for explaining the study, answering questions, and obtaining informed consent. Include a plan for ensuring that human subjects' questions will be addressed during the consent process and throughout the study.
 - Include information regarding the timing and location of the consent process.
 - Address issues relevant to the mental capacity of the potential human subject (e.g., altered capacity due to administration of any mind-altering substances such as tranquilizers, conscious sedation or anesthesia, brain injury, stress/life situations, or human subject age), if applicable.
 - Address how privacy and time for decision-making will be provided and whether or not the potential human subject will be allowed to discuss the study with anyone before making a decision.
 - Consider the need for obtaining ongoing consent or for re-assessing capacity over the course of a long-term study and describe any relevant procedures to assure continued consent.
 - Describe the plan for the consent of the individual's Legally Authorized Representative (LAR) to be obtained prior to the human subject's participation in the study. State law defines who may act as the LAR. The local IRB of record should be consulted for guidance regarding who can serve as LAR for research at the study site. Note: The PI must describe a clear intent to benefit for human subjects who cannot give their own consent to participate in the proposed clinical trial to be in compliance with 10 USC 980
 (<https://www.gpo.gov/fdsys/pkg/USCODE-2011-title10/pdf/USCODE-2011->

[title10-subtitleA-partII-chap49-sec980.pdf](#)). If applicable, please refer to the General Submission Instructions, Appendix 1, for more information.

- **Assent:** If minors or other populations that cannot provide informed consent are included in the proposed clinical study, a plan to obtain assent (agreement) from those with capacity to provide it or a justification for a waiver of assent should be provided. PIs should consult with their local IRB to identify the conditions necessary for obtaining assent.
- **Screening Procedures:** List and describe any evaluations (e.g., laboratory procedures, history, or physical examination) that are required to determine eligibility/suitability for study participation and the diagnostic criteria for entry. Please note that some screening procedures may require a separate consent or a two-stage consent process. Informed consent must be obtained prior to initiation of any procedures for the purpose of determining eligibility.
- **Risks/Benefits Assessment:**
 - **Foreseeable risks:** Clearly identify all study risks, including potential safety concerns and adverse events. Study risks include any risks that the human subject is subjected to as a result of participation in the clinical study. Consider psychological, legal, social, and economic risks as well as physical risks. If the risks are unknown, this should be stated. If applicable, any potential risk to the study personnel should be identified.
 - **Risk management and emergency response:**
 - ❖ Describe how safety surveillance and reporting to the IRB and FDA (if applicable) will be managed and conducted.
 - ❖ Describe all safety measures to minimize and/or eliminate risks to human subjects and study personnel or to manage unpreventable risks. Include safeguards and planned responses such as dose reduction or stopping criteria based on toxicity grading scales or other predetermined alert values.
 - ❖ Discuss the overall plan for provision of emergency care or treatment for an adverse event for study-related injuries, to include who will be responsible for the cost of such care.
 - ❖ Address any special precautions to be taken by the human subjects before, during, and after the study (e.g., medication washout periods, dietary restrictions, hydration, fasting, pregnancy prevention).
 - ❖ Describe any special care (e.g., wound dressing assistance, transportation due to side effects of study intervention impairing ability to drive) or equipment (e.g., thermometers, telemedicine equipment) needed for human subjects enrolled in the study.

- **Potential benefits:** Describe known and potential benefits of the study to the human subject, a specific community, or society. Articulate the importance of the knowledge to be gained as a result of the proposed research. Discuss why the potential risks to human subjects are reasonable in relation to the anticipated benefits to the human subjects and others that may be expected to result.
- **Attachment 11: Data Management (no page limit), if applicable; required for all studies recruiting human subjects: Upload as “Data_Manage.pdf”.** The Data Management attachment should include the components listed below.
 - **Data Management:** Describe all methods used for data collection to include the following:
 - **Identifiers:** Describe the unique identifiers or specific code system to be used to identify human subjects, if applicable.
 - **Confidentiality:**
 - ❖ Explain measures taken to protect the privacy of human subjects and maintain confidentiality of study data. Strategies to protect the privacy and confidentiality of study records, particularly those containing identifying information, should be addressed.
 - ❖ Address who will have access to study records, data, and specimens, including an acknowledgment that representatives of the DOD are eligible to review study records.
 - ❖ Address requirements for reporting sensitive information to state or local authorities.
 - **Data capture, verification, and disposition:** Describe how data will be captured and verified. Describe where data (both electronic and hard copy) will be stored, who will keep the data, how the data will be stored, the process for locking the database at study completion, and the length of time the data will be stored. Describe the proposed database, how it will be developed and validated, and its capability to safeguard and maintain the integrity of the data. Describe the database lock process. For FDA-regulated studies, compliance with 21 CFR 11 and appropriate data standards (such as those established by the Clinical Data Interchange Standards Consortium) is required.
 - **Sharing study results:** In cases where the human subject could possibly benefit medically or otherwise from the information, explain whether or not the results of screening and/or study participation will be shared with human subjects or their primary care provider, to include results from any screening or diagnostic tests performed as part of the study.
 - **Laboratory Evaluations:**

- **Specimens to be collected, schedule, and amount:** All specimens that will be collected for study purposes must be clearly stated. The collection schedule and amount of material collected must also be clearly described.
 - **Evaluations to be made:** Describe all evaluations that will be made for study purposes. Explain how the results of laboratory evaluations will be used to meet the objectives of the study (or to monitor safety of human subjects).
 - **Storage:** Describe specimen storage, to include location of storage, how long specimens will be stored, any special conditions required, labeling, and specimen disposition. Outline the plan to store specimens for future use to include considerations for informed consent and providing human subjects with an opportunity to decline participation in the study.
 - **Laboratories performing evaluations and special precautions:** Identify the laboratory performing each evaluation, as well as any special precautions that should be taken in handling the samples. Special precautions that should be taken by the human subject before, during, or after the laboratory procedure should be clearly defined. If transport of samples is required, describe provisions for ensuring proper storage during transport.
- **Attachment 12: Regulatory Strategy (no page limit): If submitting multiple documents, start each document on a new page. Combine and upload as a single file named “Regulatory.pdf”. (*Attachment 12 is required for human subjects studies using an investigational drug or device.*)** Provide the information requested below and provide supporting documentation as applicable.

- State the product/intervention name.

For products/interventions that do not require regulation by the FDA or an international regulatory agency:

- Explain why the product/intervention is exempt from FDA oversight. Provide confirmation that the proposed study does not require regulation by the FDA in writing from the IRB of record or the FDA. If the proposed study will be conducted at international sites, provide equivalent information relevant to the host country(ies) regulatory requirements. No further information for this attachment is required.

For products/interventions that require regulation by the FDA and/or an international regulatory agency:

- State whether the product is FDA-approved, -licensed, or -cleared, and marketed in the United States.
- If the product is marketed in the United States, state the product label indication. State whether the proposed research involves a change to the approved label indication for the route of administration, dosage level, and/or subject population. Indicate whether the proposed research involves a change that increases the risks

associated with using the product. State whether the product is being promoted for an off-label use (where promotion involves the sale of a marketed product).

- If the product is not currently FDA-approved, -licensed, or -cleared, state the planned indication/use. Indicate whether the product would be classified as a drug, device, biologic, or combination product. Indicate whether the FDA has confirmed the proposed classification. Identify the regulatory sponsor. Include a signed sponsor commitment letter acknowledging the regulatory sponsor’s understanding of all sponsor responsibilities and commitment to oversee execution of the study.
- For the BAA, if an IND or IDE is required to initiate the proposed research project, it must be submitted to the FDA prior to submission of the full proposal/application. The IND or IDE should be specific for the investigational product (i.e., not a derivative or alternate version of the product) and indication to be tested in the proposed clinical study. Provide the date of submission, application number, and sponsor for any existing FDA applications in place. If there are any existing cross-references in place, provide the application number and associated sponsor. Provide an explanation of the status of the application (e.g., past the critical 30-day period, pending response to questions raised by the FDA, on clinical hold). Provide a summary of previous meetings with the FDA on development of this product, if appropriate. A copy of the Agency meeting minutes should be included if available. Provide copies of communications from the FDA relevant to the most recent status of the IND or IDE application.
- If an IND or IDE has already been obtained for the investigational product, provide a copy of the acceptance from the FDA.
- Provide the current status for manufacturing development (e.g., manufacturer’s name, GMP-compliant lots available, status of stability testing, etc.), non-clinical development (e.g., test facility name, status of pivotal GLP toxicology studies to support phase 1 testing), and clinical development (e.g., clinical site name, safety profile, status of any completed or ongoing clinical trials).
- Describe the overall regulatory strategy and product development plan that will support the planned product indication. Include a description of the numbers and types of studies proposed to reach approval, licensure, or clearance, the types of FDA meetings that will be held/planned, and the submission filing strategy. Include considerations for compliance with current GMP, GLP, and GCP guidelines.
- **Attachment 13: Representations: Upload as “RequiredReps.pdf”.** All extramural applicants must complete and submit the Required Representations template available on eBRAP (<https://ebrap.org/eBRAP/public/Program.htm>). For more information, see the General Submission Instructions, Appendix 5, Section B, Representations.
- **Attachment 14: Suggested Collaborating DOD Military Facility Budget Format, if applicable: Upload as “MFBudget.pdf”.** If a Military Facility (MHS facility, research

laboratory, medical treatment facility, dental treatment facility, or a DOD activity embedded within a civilian medical center) will be a collaborator in performance of the project, complete a separate budget using, “Suggested Collaborating DOD Military Facility Budget Format, available for download on eBRAP “Funding Opportunities and Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>), including a budget justification for each Military Facility as instructed. The costs per year should be included on the Grants.gov Research & Related Budget Form under subaward costs. Refer to the General Submission Instructions, Section III.A.8, for detailed information.

To evaluate compliance with Title IX of the Education Amendments of 1972 (20 USC 1681(a) et seq.), the DOD is collecting certain demographic and career information to be able to assess the success rates of women who are proposed for key roles in applications in science, technology, engineering, or mathematics (STEM) disciplines. To enable this assessment, each proposal/application must include the following forms completed as indicated.

Research & Related Personal Data: Refer to the General Submission Instructions, Section III.A.3, for detailed information.

Research & Related Senior/Key Person Profile (Expanded): Refer to the General Submission Instructions, Section III.A.4, for detailed information.

- PI Biographical Sketch (five-page limit): Upload as “Biosketch_LastName.pdf”. The suggested biographical sketch format is available on the “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>) in eBRAP. The National Institutes of Health (NIH) Biographical Sketch may also be used. All biographical sketches should be submitted in uneditable PDF format.
- PI Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf”.
- Key Personnel Biographical Sketches (five-page limit each): Upload as “Biosketch_LastName.pdf”.
- Key Personnel Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf”.

Research & Related Budget: Refer to the General Submission Instructions, Section III.A.5, for detailed information.

Budget Justification (no page limit): Upload as “BudgetJustification.pdf”. The budget justification for the entire period of performance must be uploaded to the Research & Related Budget after completion of the budget for Period 1.

Project/Performance Site Location(s) Form: Refer to the General Submission Instructions, Section III.A.6, for detailed information.

Research & Related Subaward Budget Attachment(s) Form (if applicable): Refer to the General Submission Instructions, Section III.A.7, for detailed information.

NOTE: Proposals/applications from **federal agencies** must include in their budget justifications a **Federal Financial Plan**. Proposals/applications from organizations that include **collaborations with DOD Military Facilities** must comply with special requirements. Refer to the General Submission Instructions, Section III.A.5, Research & Related Budget, for detailed information.

II.D.3. Dun and Bradstreet Data Universal Numbering System (DUNS) Number and System for Award Management

Applicant organizations and all sub-recipient organizations must have a DUNS number to submit proposals/applications to Grants.gov. The applicant organization must also be registered in the Entity Management functional area of the SAM with an “Active” status to submit proposals/applications through the Grants.gov portal. Verify the status of the applicant organization’s Entity registration in SAM well in advance of the proposal/application submission deadline. Allow several weeks to complete the entire SAM registration process. If an applicant has not fully complied with the requirements at the time the federal awarding agency is ready to make a federal award, the federal awarding agency may determine that the applicant is not qualified to receive a federal award and use that determination as a basis for making a federal award to another applicant. Refer to the General Submission Instructions, Section III, for further information regarding Grants.gov requirements.

Announcement of Transition to SAM-Generated Unique Entity Identifier (UEI): Through April 2022, a transition from DUNS to the SAM-generated UEI will occur. Refer to the General Submission Instructions, Section III.1, DUNS Number, for more information on the transition and timing.

II.D.4. Submission Dates and Times

This is a continuously open announcement through September 30, 2022; therefore, reviews occur throughout the year. Pre-proposals/pre-applications may be submitted at any time throughout the 5-year period from the BAA release date to the BAA closing date (noted in [Section I](#)). An invited full proposal/application should be submitted within 90 days of the PI’s receipt of an invitation to submit. No pre-proposal/pre-application or full proposal/application may be submitted under this BAA after September 30, 2022, 11:59 p.m. Eastern Time. If an invited proposal/application is not submitted by September 30, 2022, 11:59 p.m. Eastern Time, the applicant must wait for the next available opportunity for submission, i.e., the release of the FY23 BAA (to be posted to Grants.gov October 1, 2022). No proposal/application received under this BAA will be considered for funding after 24 months from the date of submission.

II.D.5. Intergovernmental Review

This BAA is not subject to EO 12372, “Intergovernmental Review of Federal Programs.” The EO provides for state and local government coordination and review of proposed federal financial assistance and direct federal development. The EO allows each state to designate an entity to perform this function. This coordination and review is not required under this BAA.

II.D.6. Funding Restrictions

There are no specified funding limitations identified for a proposal/application submitted under this BAA. Refer to the General Submission Instructions, Section III.A.5, “Research & Related Budget,” for discussion of allowable costs, including pre-award costs and collaborations with Military Facilities.

II.D.7. Other Submission Requirements

Refer to the General Submission Instructions, Appendix 4, for detailed formatting guidelines.

II.E. Proposal/Application Review and Selection Information

II.E.1. Criteria for Research Proposals/Applications Not Including a Clinical Trial

II.E.1.a. Peer and Programmatic Review

1. Peer Review: To determine technical merit, all proposals/applications will be evaluated according to the following scored criteria, which are listed in descending order of importance:

- **Research Objectives:**
 - The degree to which the stated objectives are clear, valid, and logical.
 - For development of devices and technologies, the degree to which the performance objectives are feasible; the proposed effort demonstrates familiarity with the historical background of the problem and previous/current solutions; and the awareness of similar projects previously undertaken and related development activities.
 - The extent to which the proposed research project demonstrates an innovative approach and relates to the Research Areas of Interest identified in [Section II.A](#) and [Appendix I](#).
- **Scientific Design Excellence:**
 - The degree to which proposed plans, methods, techniques, and procedures are feasible, clear, valid, adequately referenced, and state of the art; the merit of the statistical features of the study; and the extent to which literature searches were used to document the strengths of the proposed project.
 - For development of devices and technologies, the feasibility of the proposed product/technology development plan; how well the engineering/technical design is likely to achieve the goals indicated; adequacy of the engineering/design solutions; and how well the perceived engineering/design strengths and flaws are addressed.

- To what degree the intellectual and material property plan is appropriate and demonstrates cooperating institutions' willingness and ability to resolve intellectual and material property issues.
 - How well the proposed research is designed to achieve reproducible and rigorous results, including controls, sample size estimation, randomization, statistical analysis, and data handling.
 - For clinical research studies, how well the proposal/application describes a plan to recruit subjects, including description of the inclusion and randomization criteria and whether the exclusion criteria are justified.
 - How well plans to collect specimens and conduct laboratory evaluations are addressed, if applicable. To what degree the data collection instruments, if applicable, are appropriate to the proposed study.
- **Impact/Outcomes**
 - The potential impact of the research in the field, the significance of this impact, and when it can be anticipated.
 - How the results of this research are expected to impact the intended beneficiaries.
 - To what degree the anticipated outcomes could be implemented in a dual-use capacity to benefit the civilian population and address the healthcare needs of military Service Members, Veterans, and/or their beneficiaries, if applicable.
 - How well the project outcomes will translate into clinical applications and advancements in military health and medicine.
- **Recruitment, Accrual, and Feasibility (for studies recruiting human subjects)**
 - How well the availability of human subjects for the clinical research and the prospect of their participation is addressed.
 - Whether access to the proposed human subjects population is demonstrated.
 - To what degree the recruitment, informed consent, screening, and retention processes for human subjects will meet the needs of the proposed clinical trial.
 - How well the proposal/application identifies possible delays (e.g., slow accrual, attrition) and presents adequate contingency plans to resolve them.
- **Ethical Considerations (for studies recruiting human subjects)**
 - How well the evidence shows that procedures are consistent with sound research design and, when appropriate, that these procedures are already in use for diagnostic or treatment purposes.

- Whether the level of risk is minimized and communicated through informed consent.
- How well safeguards are described and in place for vulnerable populations.
- The degree to which confidentiality and/or privacy issues are appropriately considered.
- **Transition Plan and Regulatory Strategy**
 - How well the proposal/application demonstrates feasible methods and strategies to move the project's findings to the next phase of development or clinical application.
 - Whether the proposal/application appropriately addresses available opportunities and potential barriers that could impact the progress of commercializing and/or translating the study results into clinical practice.
 - Whether the timeline for expected post-award progress is reasonable and contains appropriate milestones and deliverables for advancing the study results toward clinical impact.
 - Whether the funding strategy described to bring the anticipated research outcomes to the next level of development is reasonable and realistic.
 - To what degree the proposed collaborations and other resources for providing continuity of development are established and/or achievable.
 - How well the plan is described for distribution of the findings or intervention to the civilian and/or military communities.
 - How well the proposal/application identifies intellectual property ownership, describes any appropriate intellectual and material property plan among participating organizations (if applicable), and addresses any impact of intellectual property issues on product development and subsequent government access to products supported by this BAA/funding opportunity.
 - Whether the applicant has demonstrated that they have access to all intellectual property rights necessary for development and commercialization and evidence that the government has the ability to access such products or technologies.
- **PI and Key Personnel Qualifications:** The qualifications, capabilities, and experience of the proposed PI and other key personnel to demonstrate that the proposed staff has the knowledge, technical expertise, and management skills to achieve the proposed objectives as well as the time available for the percentage of efforts indicated for the project.
- **Facilities and Resources:** The proposed facilities and equipment, population resources, or unique combinations of these, to demonstrate that the organization has the necessary facilities and resources required for accomplishing the proposed objectives.

- **Budget:** The degree to which the budget reflects the actual needs of the proposed work and is thoroughly detailed and fully justified so that the government can evaluate and determine the costs to be allocable, allowable and reasonable, and commensurate with the complexity and nature of the research proposed.

2. Programmatic Review: To make funding recommendations, the following criteria will be used by programmatic reviewers:

- Scientific peer review results
- Adherence to the intent of the award mechanism
- Program portfolio composition and priorities
- Relative military benefit
- Relative innovation, impact, and translatability

NOTE: Military-relevant research must be responsive to the healthcare needs of the Armed Forces, family members of the Armed Forces, and the U.S. Veteran population. Proposals/applications must address a military-relevant health problem responsive to one of the Research Areas of Interest identified in [Section II.A](#) and [Appendix I](#).

II.E.2. Proposal/Application Selection Process

All invited proposals/applications are evaluated by USAMRDC scientists, other federal agency representatives, outside scientists with diverse expertise, clinicians, consumers, or combinations thereof, using a two-tier review process. The first tier is peer review of proposals/applications against established criteria for determining technical merit. The second tier is programmatic review based on established criteria for determining relevance to the mission of the USAMRDC and its programs.

All USAMRDC review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign agreements to (1) protect the confidentiality of the information in the proposal/application and (2) not disclose evaluation information outside the panel. Violations of confidentiality can result in the dissolving of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization's proposal/application. Violations by panel members or applicants that compromise the confidentiality of the review process may also result in suspension or debarment from federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to another third party by military personnel or employee of the federal government is a crime in accordance with 18 USC 1905.

After the two-tier evaluation, proposals/applications recommended for funding may be prioritized. A prioritized listing of alternates (deferred decisions) may also be prepared, when warranted. Subsequent awards depend upon the availability of funds and fulfillment of

requirements and priorities determined to exist at the time of award. In some cases, funding priorities may change as certain scientific tasks are addressed and new mission assignments arise.

If selected for funding, the award may also be dependent on the organization providing adequate additional regulatory documentation, such as human subjects/anatomical substances/use of cadavers protocols and approvals, animal subjects protocols and approvals, and environmental information. The award may also be dependent on additional supporting administrative and budgetary information.

II.E.3. Integrity and Performance Information

Prior to making an award where the federal share is expected to exceed the simplified acquisition threshold (currently \$250,000), over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in FAPIIS.

An applicant, at its option, may review FAPIIS, accessible through SAM, and submit comments to FAPIIS on any information about itself that a federal awarding agency previously entered and is currently available in FAPIIS.

The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics, and record of performance under federal awards when determining an organization's qualification prior to award, according to the qualification standards of the DoDGARs, Section 22.415.

II.E.4. Notification of Proposal/Application Review Results

Each PI and organization will receive email notification via eBRAP of the proposal/application status. Notifications should be sent within 180 calendar days of submission. Each PI will receive a peer review summary statement on the strengths and weaknesses of the proposal/application.

A recommended for funding notification is NOT an authorization to begin performance or a guarantee of an award. Awards are contingent upon availability of funding, adequacy of supporting documentation submitted, fulfillment of all requirements, and completion of successful negotiations. Authorization to begin performance will be received via an award document (Contract, Grant, Other Transaction, or Cooperative Agreement, as applicable) signed by the USAMRAA Contracting Agreements, or Grants Officer. Awards may be issued at any time throughout the year.

II.F. Federal Award Administration Information

II.F.1. Federal Award Notices

The PI should receive disposition regarding the full proposal/application via an email from eBRAP within 180 days of submission. **A recommended for funding notification is NOT an authorization to begin performance nor a guarantee of an award.**

The awarding agency will be the USAMRAA. The USAMRAA Contracting, Agreements and Grants Officers are the only individuals authorized to obligate funds and bind the federal government.

Authorization to begin performance will be received via an award document (contract, grant, or cooperative agreement, as applicable) signed by the USAMRAA Contracting, Agreements, or Grants Officer. No commitment on the part of the government should be inferred from discussions with any other individual.

Awards will be made at any time throughout the year and are contingent upon availability of funding, adequacy of supporting documentation submitted, fulfillment of requirements, and completion of successful negotiations. No proposal/application submitted under this BAA will be considered for funding after 24 months from the date of submission to Grants.gov. Refer to the General Submission Instructions, Appendix 2, Section D, Award Notices, for additional information.

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this BAA. Refer to the full text of the USAMRAA General Research Terms and Conditions for Institutions of Higher Education, Hospitals, and Non-Profit Organizations and the USAMRAA General Research Terms and Conditions for For-Profit Organizations available at <https://www.usamraa.army.mil/Pages/Resources.aspx> for further information.

II.F.1.a. PI Changes and Award Transfers

Refer to the General Submission Instructions, Appendix 2, Sections L and M, for general information on changes to PIs and organizational transfers.

II.F.2. Administrative and National Policy Requirements

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this BAA.

Applicable requirements in the FAR, found in 48 CFR, Chapter 1; DFARS, found in 48 CFR, Chapter 2; and AFARS, found in 48 CFR, Chapter 51, apply to contracts resulting from this BAA.

Refer to the General Submission Instructions, Appendix 2, for general information regarding administrative requirements.

Refer to the General Submission Instructions, Appendix 5, for general information regarding national policy requirements.

Refer to full text of the latest [DOD R&D General Terms and Conditions](#), the [USAMRAA General Research Terms and Conditions with Institutions of Higher Education, Hospitals, and Non-Profit Organizations: Addendum to the DoD R&D General Terms and Conditions](#) and the [USAMRAA General Research Terms and Conditions with For-Profit Organizations](#) for further information.

II.F.3. Reporting Requirements

Refer to the General Submission Instructions, Appendix 2, Section A, for general information on reporting requirements.

Technical/scientific reporting requirements may include:

- Quarterly and/or annual progress reports
- Final progress report
- In-progress reviews
- Quad charts: The Quad Chart template is a one-page Word document or PowerPoint file that must be downloaded from eBRAP at <https://ebrap.org/eBRAP/public/Program.htm> and completed for submission and application.
- Inclusion Enrollment Reporting Requirement (only required for clinical research studies): Enrollment on the basis of sex/gender, race, and/or ethnicity will be required and will be reported with each annual and final technical report. The suggested Inclusion Enrollment Report format is available on the “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>) in eBRAP.

The government may request additional reports, which will be identified prior to award.

II.G. Federal Awarding Agency Contacts

II.G.1. eBRAP Help Desk

Questions related to BAA content or submission requirements as well as questions related to the submission of the pre-proposal/pre-application through eBRAP should be directed to the eBRAP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. Eastern Time. Response times may vary depending upon the volume of inquiries.

Phone: 301-682-5507

Email: help@eBRAP.org

II.G.2. Grants.gov Contact Center

Questions related to full proposal/application submission through the Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. federal holidays). Note that the eBRAP Help Desk is unable to provide technical assistance with Grants.gov submission.

Phone: 800-518-4726 (International: 1-606-545-5035)

Email: support@grants.gov

Sign up on Grants.gov for “send me change notification emails” by following the link on the Synopsis page for the BAA or by responding to the prompt provided by Grants.gov when first downloading the submission package. If the submission package is updated or changed, the original version of the submission package may not be accepted by Grants.gov.

II.H. Other Information

II.H.1. Contractor/Recipient Qualification

Refer to the General Submission Instructions, Appendix 3, for general information on required qualifications.

In addition to other information provided herein, by submitting a proposal/application and accepting an award, the organization is: (1) certifying that the investigators’ credentials have been examined and (2) verifying that the investigators are qualified to conduct the proposed study and to use humans and/or animals as research subjects, if proposed. Investigators include all individuals, regardless of ethnicity, nationality, or citizenship status, who are employed by, or affiliated with, an eligible organization.

Should the PI of a funded project leave the award organization, both the PI and organization must contact the USAMRAA as soon as possible to discuss options for continued support of the research project. Every effort should be made to notify the USAMRAA prior to the PI leaving the organization.

II.H.2. Proprietary Information

Do not include any proprietary information in the pre-proposal/pre-application. Proprietary information should *only be included* in the full proposal/application *if necessary for evaluation purposes*. Abstracts of all funded proposals/applications will be posted publicly. *Therefore, do not include proprietary information in the abstracts.*

Conspicuously and legibly, mark any proprietary information that is included in the full proposal/application. Identify any proprietary information to be provided to the government and indicate whether the applicant will request a waiver of government purpose rights.

II.H.3. Administrative Actions

After agency receipt of proposals/applications from Grants.gov, the following administrative actions may occur:

II.H.3.a. Rejection

The following will result in administrative rejection of the proposal/application:

- Project Narrative exceeds the page limit.
- Project Narrative is missing.

- Budget Form contains only zeros.
- Full proposal/application submission in the absence of an invitation.
- For proposals/applications that include a clinical trial, the following may result in administrative rejection:
 - Human Subject Recruitment and Safety Procedures ([Attachment 6](#)) is missing.
 - Intervention ([Attachment 7](#)) is missing.
 - Data Management ([Attachment 8](#)) is missing

II.H.3.b. Modification

- Pages exceeding the specific limits may be removed prior to review for all documents other than the Project Narrative.
- Documents not requested may be removed.
- Following proposal/application submission to Grants.gov, the PI will receive an email request from eBRAP to review, modify, and verify the proposal/application submitted to Grants.gov. During this verification period, the PI may upload missing documents (excluding those listed above in [Section II.H.3.a, Rejection](#)), replace files, and re-categorize files. These modifications must be completed by the end of the 5-day proposal/application verification period; otherwise, the proposal/application will be reviewed as submitted. If either the Project Narrative exceeds the page limit or the Budget Form contains only zeros, an updated Grants.gov submission package must be submitted via Grants.gov as a “Changed/Corrected Application” with the previous Grants.gov Tracking ID.

II.H.3.c. Withdrawal

The following may result in administrative withdrawal of the pre-proposal/pre-application or proposal/application:

- Federal agency personnel involved in the review process and/or with making funding recommendations are named as being involved in the research proposed or found to have assisted in the pre-proposal/pre-application or proposal/application processes, including, but not limited to, concept design, proposal/application development, budget preparation, and the development of any supporting documentation. ***If formal collaboration with Military Facility personnel is planned (i.e., included in the proposal/application in performance of the research), this prohibition is not applicable. However, these Military Facility personnel are prohibited from being involved in the review process and/or with making funding recommendations.***
- Inclusion of any employee of USAMRDC review contractors in pre-proposal/pre-applications or full proposals/applications for funding without adequate plans to manage COIs. Refer to General Submission Instructions, Appendix 3, Section D, for detailed information.

- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review process to gain protected evaluation information or to influence the evaluation process.
- The full proposal/application does not propose the same research project as described in the pre-proposal/pre-application.
- The full proposal/application budget differs significantly from the budget included in the pre-proposal/pre-application.
- Proposed research of work that has been funded or selected for funding may result in withdrawal.
- For studies requiring an IND or IDE, documentation of IND/IDE submission and/or approval is not provided.

II.H.3.d. Withhold

Proposals/applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the USAMRAA Contracting, Agreements, or Grants Officer for a determination of the final disposition of the proposal/application.

II.H.4. Common Submission Problems

- Failure to enter an email address for change notifications under the BAA in Grants.gov for notifications on any modification made to the initial posting.
- Attachments are uploaded into the incorrect form on Grants.gov forms. (See the appropriate Proposal/Application Submission Checklist in [Section II.I.](#))
- Failure to contact the Grants.gov Help Desk when needed.
- Failure to include attachments.
- Inability to locate attachment forms. (Select “Search Grants” at <https://www.grants.gov> and enter W81XWH18SBAA1 in the “Opportunity Number” block; or in the “CFDA” block, enter 12.420, and perform a “Search.” Under the “Opportunity Number” column, look for number W81XWH18SBAA1 in the list.)
- Use of “illegal” characters in attachment titles.
- Attachments exceed size limits.
- Upload attempts of unacceptable attachments: bitmap, TIFF, etc.
- Duplicate upload of documents.

II.I. Checklist for Research Proposal/Application Submission Not Including a Clinical Trial

Grants.gov Application Components	Upload Order	Action	Completed
SF424 (R&R) Application for Federal Assistance		Complete form as instructed.	
Attachments Form	1	Project Narrative: Upload as Attachment 1 with file name "ProjectNarrative.pdf"	
	2	Supporting Documentation: Upload as Attachment 2 with file name "Support.pdf"	
	3	Technical Abstract: Upload as Attachment 3 with file name "TechAbs.pdf"	
	4	Lay Abstract: Upload as Attachment 4 with file name "LayAbs.pdf"	
	5	Statement of Work: Upload as Attachment 5 with file name "SOW.pdf"	
	6	Impact/Outcomes Statement: Upload as Attachment 6 with file name "Impact.pdf"	
	7	Military Relevance Statement: Upload as Attachment 7 with file name "MilRel.pdf"	
	8	Data and Research Resource Sharing Plan: Upload as Attachment 8 with file name "Sharing.pdf"	
	9	Post-Award Transition Plan: Upload as Attachment 9 with file name "Transition.pdf"	
	10	Human Subject Recruitment and Safety Procedures: Upload as Attachment 10 with file name "HumSubProc.pdf," if applicable	
	11	Data Management: Upload as Attachment 11 with file name "Data_Manage.pdf," if applicable	
	12	Regulatory Strategy: Upload as Attachment 12 with file name "Regulatory.pdf," if applicable	
	13	Representations: Upload as Attachment 13 with the file name "RequiredReps.pdf"	
	14	Suggested Collaborating DOD Military Facility Budget Format: Upload as Attachment 14 with file name "MFBudget.pdf," if applicable	
Research & Related Personal Data		Complete form as instructed.	

Research & Related Senior/Key Person Profile (Expanded)		Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field.	
		Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field.	
		Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field.	
		Attach Previous/Current/Pending (Support_LastName.pdf) for each senior/key person to the appropriate field.	
Research & Related Budget		Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field.	
Project/Performance Site Location(s) Form		Complete form as instructed.	
Research & Related Subaward Budget Attachment(s) Form		Complete form as instructed.	

APPENDIX I: RESEARCH AREAS OF INTEREST

I. Military Infectious Diseases Research Program

Research and development of solutions for the prevention, treatment, and diagnosis of infectious diseases

- **Prophylactics:** The MIDRP supports the development of solutions to prevent infectious disease threats to eliminate their impacts on operational readiness. Prevention is the most desirable infectious disease countermeasure because it prevents disease from occurring (vs. treatment post-infection), is the most cost-effective approach, and reduces unit loss rate. The MIDRP supports discovery, optimization, development of animal models, efficacy testing *in vitro*, efficacy and safety testing in validated preclinical animal models, cGMP manufacture, safety and efficacy testing in clinical trials of novel prophylactics for the following:
 - Bacterial diarrhea
 - Combat wound infections (from complex traumatic penetrating injuries)
 - Dengue fever
 - HIV
 - Hantavirus
 - Emerging infectious diseases
 - Pathogen agnostic prophylactics targeting diseases/pathogens listed above
- **Treatments:** The MIDRP supports the development of solutions to treat infectious disease threats to eliminate their impacts on operational readiness. Improved treatment solutions for infectious disease casualties are necessary to return Warfighters to competition. The MIDRP supports discovery, optimization, development of animal models, efficacy testing *in vitro*, efficacy and safety testing in validated preclinical animal models, cGMP manufacture, safety and efficacy testing in clinical trials of novel treatments for the following:
 - Combat wound infections (from complex traumatic penetrating injuries)
 - Dengue fever
 - Hantavirus
 - Emerging infectious diseases
 - Pathogen agnostic treatments targeting diseases/pathogens listed above

- **Diagnostics:** The MIDRP supports the development of solutions to diagnose infectious disease threats to eliminate their impacts on operational readiness. Improved diagnostic solutions for infectious disease casualties are necessary to accurately inform treatment decisions, and ultimately return Warfighters to competition. The MIDRP supports the identification of targets for diagnostic assay design, optimization of assays on selected platforms, validation and testing of diagnostic assays and platforms for the following:
 - Diagnostics for the pre-symptomatic/early symptomatic detection of wound infections and/or sepsis in far forward austere environments
 - Diagnostics for the pre-symptomatic/early symptomatic detection of bacterial and viral infections in far forward austere environments

II. Combat Casualty Care Research Program

A. Research and development of technologies to stop blood loss, resuscitate the casualty, and limit the immediate, short-, and long-term deleterious consequences of severe hemorrhage: Research focused on the pre-hospital setting including point of injury and scenarios in which a casualty cannot be transported through traditional levels of care (i.e., PC) are of high interest. Included in this area of interest are diagnostics and therapeutics to predict, diagnose, prevent, and treat coagulopathy of trauma and non-invasive or minimally invasive sensors to detect and warn of impending vascular collapse and/or significant tissue damage due to perfusion deficits. Examples of specific products include local and systemic hemostatic agents or devices (exovascular or endovascular) for control of vascular disruption and subsequent compressible and non-compressible hemorrhage, treatments to sustain or enhance oxygen delivery and perfusion of vital tissues and organs, and equipment, procedures, and blood product or other fluids and adjuncts for effective resuscitation. Also of interest are the improved preservation, storage, transportability, and processing of red blood cells, platelets and plasma, and other blood or blood-like substitutes.

B. Research and development of technologies to diagnose and to limit the immediate, short-, and long-term impairments that follow TBI: Knowledge and materiel solutions that seek to improve the far-forward capabilities of military diagnostic, characterization and treatment for the spectrum of TBI severities. Objective diagnosis and treatment of brain injury are recognized as high priorities. Research objectives in this area includes (but is not limited to):

- Developing life-saving resuscitation interventions for TBI and polytrauma/complex injury.
- Fielding point-of-injury therapeutic interventions to mitigate secondary effects of brain injury.
- Enabling far-forward, rapid diagnostic capabilities to diagnose and monitor TBI in a prolonged field care environment, with an emphasis on non- or minimally-invasive technologies/assays.

- Developing monitoring and recording technologies for management and maintenance of TBI in a prolonged field care environment.

C. Research and development of technologies to diagnose and reduce acute secondary organ damage: Secondary damage to organs frequently occurs after severe trauma and resuscitation. The CCCRP is interested in materiel and/or devices that can reduce acute secondary organ damage such as ischemia/reperfusion injury, cell death, general organ failure, and secondary brain damage. Technologies to sustain or support single- and multiple-organ injury and failure are also of interest to the CCCRP. These objectives include methods to reduce cellular demand for oxygen and metabolic substrates and therapeutics to modulate the immune response to traumatic injury as well as single- and multiple-organ support or replacement technologies (extracorporeal). In addition, the utilities of these modalities during (and the effects of longer distance) en route care on the critically injured casualty are also of interest.

D. Research and development into the delivery of care during transport: An important element of combat casualty care is the transport of patients from the initial point of injury and throughout the continuum of care. Accordingly, the CCCRP is interested in improving and maintaining optimal clinical outcomes for en route care. Identifying feasible ways to mitigate the stresses of flight and/or transport (such as hypobaric, hypoxia, vibration, and g-forces) in an austere/constrained environment and the impact on clinical outcomes (such as healing rates, pain, infection rates, etc.) are particularly important. Additionally, establishing either timeframes or ways to measure the appropriate time to transport patients with critical injuries (including neurotrauma, burns, lung injuries, and musculoskeletal injuries) is a critical element to improving outcomes. Solutions that improve the capacity and capability of en route care delivery, including development autonomous care and critical care solutions will be considered.

E. Research, development, and translation into clinical practice of novel/optimized treatments for severe burn injuries: Safe and effective therapies and technologies are needed to provide early, life-saving burn fluid resuscitation, and early/ongoing care for severe burn skin (and underlying tissue) wounds as well as burn inhalation injury across the continuum of care. Prioritized approaches will be amenable for use by non-specialist care givers, logistically practicable in austere environments, and simplified for self- and buddy-aid where feasible. Burn injury management strategies of highest interest will advance the standard of care available to stabilize burn casualties close to the point of injury, potentially during prolonged delay of evacuation to definitive care by burn specialists, with additional consideration for utility in mass casualty events. Advanced solutions to stabilize burn wounds and promote/accelerate healing, optimize burn fluid resuscitation, preclude development of complications (e.g., dysregulated inflammatory and immune physiology driven by severe burn trauma, burn wound infection) are particularly sought. Advancements that enhance both burn treatment capability at all echelons of care and capacity especially in the prehospital environment are of interest.

F. Pain Management: The primary interest of the Pain Management program area is management of acute pain associated with traumatic or combat-related injuries, with a secondary interest in early interventions to prevent pain chronification. The CCCRP's

specific needs include development of alternative interventions to current opioid analgesics administered on the battlefield and in resource-limited environment by the medic/corpsman; pain management strategies that promote military readiness (including treatments with limited side effects, e.g., no effect on respiration or cognitive function); treatments for the variety of pain etiologies resulting from polytrauma; understanding and treatments for comorbid physical and mental health factors that impact pain; development of strategies for identifying and addressing biopsychosocial aspects of pain; solutions for pain management under prolonged care conditions; chronic pain treatment; and pain chronification prevention. Field expedient regional analgesia solutions will also be considered.

G. Regenerative Medicine: Regenerative medicine involves the use of innovative technologies such as scaffolds and tissue engineering, growth factors, and cell-based treatments to restore Service Members who have suffered combat-related injuries. Research topics of particular interest include those directed toward the use of regenerative medicine-based technologies to provide early field solutions for tissue coverage and wound healing, blood product production, hemostasis, volumetric muscle loss and vascular defects.

H. Military Medical Photonics: The Military Medical Photonics program focuses on the uses of lasers and other light source technology to develop applications in medicine, photobiology, surgery, and closely related materials sciences to directly address combat casualty care and other military medical problems. The efforts proposed may be basic or applied research, and must have direct relevance to combat casualty care or other military operational medicine priorities. Applications which leverage multidisciplinary teams of physicians, biomedical scientists, physical scientists, and engineers and collaboration with military investigation are highly encouraged.

III. Military Operational Medicine Research Program

A. Injury Prevention and Reduction: This area of research addresses the requirement to provide the biomedical basis for countermeasures and scalable strategies that prevent and mitigate Service Member injuries and performance decrements occurring in training and operational (including close combat) environments, decrease attrition and medical cost, minimize personal impact to the Service Member, and promote, optimize, and enhance readiness. The primary needs of the Injury Prevention and Reduction portfolio are developing and validating RTD physical performance standards following musculoskeletal injury; understanding the physiological impact of exposure to repetitive low-level blast in order to validate military safety standards and health hazard assessment prediction tools to prevent brain, sensory, and lung injury; understanding effectiveness of personal protective equipment for blast, blunt, accelerative and emerging directed energy threats; understanding the bioeffects from exposure to emerging directed energy threats (e.g., laser, microwave, and radiofrequency waves); understanding the physiology of injury and repair mechanisms and their interrelationships with both modifiable and non-modifiable factors (e.g., environment, nutrition, sleep, stress, situational and cognitive awareness, genetics, sex, age) to promote effective interventions; providing validated injury criteria with animal models and postmortem human subject against blunt and ballistic threats to inform helmet and body armor developments; developing injury thresholds against directed energy threats; developing interventions to mitigate musculoskeletal injury risk and optimize and enhance

performance in complex military systems; and developing and validating assessment tools and strategies to promote Service Member physical performance optimization (individual and group). Research needs also encompass identification and validation of cognitive/brain health factors that impact physical performance. Finally, “omics”-level efforts and genetic indicators that identify individual strengths/vulnerabilities to injury and performance are important to guide training and operational strategies that maximize readiness and lethality. Development goals include decision aids, biomedical guidance, assessment techniques, and validated metrics (including biomarkers). Coordination with medical DOD laboratories such as the U.S. Army Aeromedical Research Laboratory and Walter Reed Army Institute of Research, other DOD services (Navy, Marines, Air Force), and academia/universities and support of the U.S. Army Training and Doctrine Command, Center for Initial Military Training and U.S. Army Forces Command (including the Holistic Health and Fitness System) is highly encouraged.

B. Psychological Health and Resilience: The Psychological Health and Resilience research program area is interested in research aimed at maximizing resilience; enhancing readiness and psychological health; and decreasing PTSD, depression and anxiety disorders, suicide, and risk behaviors (e.g., substance abuse, anger/aggression, sexual harassment and assault, and interpersonal workplace and domestic violence within the military). Additional psychological health areas of interest include military-related grief, guilt, or loss issues; moral injury; interdisciplinary and universal prevention and life-skills training strategies to mitigate negative psychological health trajectories; and reduction of stigma and other barriers to psychological healthcare-seeking. The MOMRP has interest in understanding and addressing psychosocial/psychological health challenges unique to military families, women Service Members, Reserve and Guard, and lesbian, gay, bisexual, and transgender Service Members. This research area focuses on the development and validation of effective training and prevention interventions, screening and assessment strategies, and treatment and rehabilitation interventions that address the psychological health topic areas. In addition, this research area focus may include development and validation of effective evidence-based training and prevention interventions for concussion/mild TBI. Research areas of particular interest include studies to elucidate underlying mechanisms of PTSD risk and treatment response; studies addressing PTSD comorbidities (including, but not limited to, PTSD, concussion, alcohol and other drug abuse, sleep disturbance, mood disorders, suicidality, and interpersonal psychosocial factors); studies focused on enhancing translation, implementation, and uptake of evidence-based strategies and treatments; research focused on designing and testing far-forward interventions to mitigate risk of PTSD development immediately after exposure to trauma; establishing validated objective RTD standards following psychological injury; and research focused on community/systems-level health psychology approaches appropriate for military populations. Proposals/applications that incorporate and evaluate leveraging of technology (e.g., telemedicine, remote monitoring, biosensors, advance immunologic testing, and health information technologies) and leverage existing resources (to including mining/use of medical record data) and infrastructure to support psychological risk prevention and management, lifecycle logistics, and sustainability are encouraged. Also of interest are rigorous studies on complementary and integrative health (CIH) approaches spanning mind/body, movement, natural products, non-Western medicine approaches and spiritual practices, along with validation studies of CIH therapies. Research topics of particular interest include those directed at evaluating efficacy of

cognitive training approaches to promote resilience and prevent/mitigate acute negative responses to psychological trauma and promote readiness; and the development of a systematically applied set of therapeutic services designed to mitigate psychological disorders by changing unhelpful thought patterns and unhealthy behaviors, reducing emotional distress, and restoring function and quality of life.

- C. Physiological Health and Performance:** This area of research develops biomedical countermeasures to sustain Service Member health and operational effectiveness. It informs military policy, training, Clinical Practice Guidelines (CPG), and the development of materiel solutions to establish, sustain, optimize, and monitor Service Member health, physiological factors of resilience, and cognitive and physical performance throughout the military lifecycle, including training, deployment, reset, and injury recovery cycles. This research area aims to prevent or mitigate the negative effects of operational and training stressors on the readiness, performance, and fitness of Service Members, as well as safely and ethically enhance performance with evidence-based biomedical and materiel personalized strategies based on a systems medicine approach. Studies may include, but are not limited to, those that investigate the use of dietary supplements and nutritional and behavioral interventions to mitigate threats to readiness, operational health, and performance. Research also aims to develop healthy sleep and fatigue management strategies, strategies that exploit individual differences in sleep loss resilience, and strategies that promote individualized resilience to various operational stressors and injuries. Physiological health and performance research also encompasses work focusing on cognitive performance. Basic, applied, and advanced research studies utilizing technologies and strategies to monitor and promote Service Member and family readiness and health to support the Army Surgeon General's Performance Triad.
- D. Environmental Health and Protection:** This area of research includes assessment and sustainment of health, force readiness, and the operational effectiveness of Service Members exposed to harsh operational environments including altitude, cold, heat, undersea, and exposures in the arctic, and exposures to environmental toxicant health hazards in the dense urban and subterranean environments, and/or a combination of multi-environmental stressors. Studies proposed may include, but are not limited to, methods for effective monitoring of environmental exposures in individuals and populations and assessment of health risks following exposures to environmental stressors. This research also includes development of policy, training, mission planning/management tools, decision aids, knowledge and materiel solutions, physiological status monitoring systems, interventions, and reset solutions to sustain Service Member readiness, and health and operational effectiveness to environmental stressors encountered during extreme training or operations. In addition, research identifies biomarkers of exposure, dosimetry, and risk management to environmental health hazards, neurological and physical assessment tools for optimizing performance of the Service Member exposed to extreme operational environments, biomarkers of complex exposures, and health effects in support of military operational requirements. Research also focuses on developing wearable solutions that are small size, low weight, small cube, and have minimal power requirements for real-time physiological status monitoring in extreme training and operational environments.

IV. Medical Biological Defense Research Program

A. Viral, Toxin, and Bacterial Studies

- Identification and characterization of organisms and toxins. Molecular antigenic analysis; development of diagnostic assays; studies on structure and function that are related to mechanisms of action, binding, internalization, and interaction with the immune system and neutralizing antibodies; investigation of pathogenesis and immunology that will inform and enable decisions regarding the optimal approach to disease prevention and control. Specific long-term goals include development of physiological support methodologies, diagnostic tests, rational prevention and control strategies, and improvement of existing products.
- Vaccine development, with emphasis on protection from aerosolized agents, molecular approaches for development of vaccines, measurement of relevant cellular and humoral protective immune responses, and expression or production of protective antigens using recombinant technology. Development of vaccines for specific toxins and disease agents involving the generation, selection, and characterization of attenuated strains or inactivated purified antigen preparations, to include polyvalent vaccines that are more broadly effective. Safer means of passive immunization such as production of human monoclonal or modified antibodies that are de-speciated are also of interest. Identification of surrogate markers of protection for the agents identified above and development of assays to assess such protection are needed.
- Development of improved methods for delivery of vaccines, including adjuvants, nucleic acid vaccines, methods for oral or nasal immunization with inactivated, live, and subunit antigens; sustained release formulations; and development of methods for delivery of antigens for specific induction of mucosal immunity and development of methods to enhance appropriate immune responses to include co-delivery of cytokines.
- Preparation of research quantities of highly purified and characterized toxins as well as studies on basic chemistry, mechanisms of action, metabolism, and excretion.

B. Drug Development: Development, synthesis, and testing of compounds that possess antiviral, antibacterial, immunomodulatory, or antitoxin activities, with emphasis on compounds that provide broad, non-specific protection against viruses, bacteria, and toxins as described above. Studies of their pharmacokinetics and other measurements relevant to more effective drug use are also of interest, as is the development of lead compound(s) that are potent, active-site inhibitors that may include combinatorial-derived organic molecules and/or rationally designed transition-state substrate analogs. Testing for potency is required. Approaches that will be considered include, but are not limited to, computational chemistry, combinatorial organic synthesis, high-throughput in vitro screening, and x-ray analysis of ligand-toxin co-crystals.

Research areas of interest include:

- Discovery of novel or unique biochemical elements or compounds with antiviral, antibacterial, or antitoxin activity against biological organisms.
- Development of testing models for evaluation of compounds effective against toxins of several classes, including pre- and post-synaptic toxins, membrane-damaging toxins, and toxins that inhibit protein synthesis and others.
- Mechanism of action studies of immunomodulators, including characterization of effector cells (lymphocytes, macrophages), effector mechanisms, ancillary effects on other cells of the immune system, and production and characterization of cytokines released as a consequence of immunomodulation.
- Development of novel treatments to reverse paralysis in nerve terminals exposed to botulinum neurotoxin (BoNT) serotypes A, B, E, or F, with emphasis on the following objectives: (a) development of clinically feasible treatments to block the catalytic activity of the BoNT light chain; (b) treatments to accelerate recovery from paralysis-induced atrophy by targeting skeletal muscle regenerative pathways; and (c) identification and development of novel chemical scaffolds for small molecule inhibitors of the catalytic activity of the light chain of BoNT serotype A. While there may be limited funds available for development of promising approaches, this effort is predominantly focused on the accelerated development of clinically viable treatments with existing efficacy data.

C. Identification, Diagnosis, and other Medical Interventions: The investigation and evaluation of sensitive and specific methods of identifying and diagnosing both antigens and antibodies of viruses, bacteria, and rickettsia in biological materials. Development of sensitive and specific immunologic, chemical, or biological assays for the rapid (within minutes) and reliable (1) diagnoses of acute diseases due to agents of potential biological threat and (2) identification of toxins or their metabolites in biological samples. Assay may include antigen, antibody, or metabolite detection or the use of nucleic acid probes or synthetic antigens. In addition, there is interest in the development of rapid identification and diagnostic methods for the assay of toxins, metabolites, and analogs in clinical specimens. Finally, the program is interested in any other medical interventions, techniques and treatments that show promise in supporting survival and/or recovery of biological or toxin-exposed casualties.

D. Biosurveillance (BSV): The process of gathering, integrating, analyzing, and communicating a range of information that relates to health threats for people, animals, and plants to help inform decisions and provide for increased global health security. The Joint Biosurveillance Common Framework (JBCF) will be the first materiel solution and provides a single enterprise environment that supports collaboration, data sharing, and coordination between/among multiple BSV stakeholders. The JBCF and future BSV applications, tools, and devices will provide a conduit between the medical, physical, and operational communities. This topic includes:

- Algorithms for rapid identification of baseline deviation; novel/unknown pathogens, naturally occurring versus intentional release.
- Models to predict the likelihood of an outbreak, forecast the associated epidemic curves and impacts of interventions, and update forecast based on field (and simulated) data.
- Applications to engage citizens via social media, crowd sourcing, gaming, etc.

In addition, two specific topics currently of interest are:

- Next-generation analytic capabilities for BSV: The objective is to develop next-generation methodologies to enhance analytic capabilities in the detect-identify-respond timeline for a bioevent. Research should be exploratory, with a low-technology readiness level, and should address long-term challenges in threat surveillance. Efforts should significantly contribute to the current body of knowledge and lead to new concepts for technology application that may have impact on future BSV analytic capabilities.
- Biosurveillance Ecosystem (BSVE) Analytics 2.0: The objective is to ensure state of the art technologies are made rapidly accessible through the BSVE. This topic seeks to develop analytic applications to synthesize and interrogate multiple sources of data to provide high confidence in the prediction, early warning, and forecasting (inclusive of mitigation strategies) of disease events. Metrics shall be devised such that successful utilization of these analytic tools will result in a measurable impact on the bioevent timeline. Efforts in this area should result in flexible, extensible, and sustainable analytics and models that are designed to plug into the BSVE as à-la-carte services rather than as standalone capabilities.

V. Medical Chemical Defense Research Program

- Characterizing the mechanisms of vesicant agent pathophysiology to identify medical countermeasures against vesicant agents.
- Developing innovative models of the pathophysiology of vesicant agent injury.
- Identifying and/or evaluating innovative candidate medical countermeasures against vesicant agents.
- Identifying, exploring, and developing innovative clinical diagnostic, prognostic, and management approaches to vesicant agent casualties.
- Characterizing the ocular lesions associated with vesicant agent exposures; developing treatments to ameliorate these injuries.
- Characterizing the mechanisms of nerve agent-induced seizures and resulting pathophysiology to identify medical countermeasures against nerve agent-induced seizures.
- Identifying, synthesizing, and/or evaluating innovative candidate medical countermeasures against nerve agent-induced seizures.

- Developing innovative models of the pathophysiology of nerve agent-induced seizures.
- Developing catalytic and/or stoichiometric chemical warfare agent scavengers from biological molecules (e.g., antibodies and enzymes) that provide protection against nerve agent incapacitation and lethality for extended periods following their administration.
- Developing innovative models for evaluation of chemical warfare agent scavengers.
- Identifying, expressing, synthesizing, and/or evaluating biotechnologically derived or pharmaceutically based scavengers as candidate medical countermeasures against chemical warfare agents.
- Developing and evaluating custom-synthesized pharmaceuticals based on a detailed understanding of the pathophysiology and mechanisms of action of the chemical warfare agent structure and the function of the intended target molecule.
- Developing catalytic and/or stoichiometric additives for use in skin protectants, or decontaminants, to protect against chemical warfare agents, especially vesicant and nerve agents.
- Developing innovative models for evaluation of catalytic and/or stoichiometric additives in skin protectants or decontaminants.
- Developing candidate formulations for skin protectants or decontaminants containing catalytic and/or stoichiometric additives and evaluating these formulations against chemical warfare agents.
- Characterizing the pathophysiology and natural progression of chemical warfare agent-induced damage to human tissues.
- Developing and validating innovative techniques for rapid and accurate analysis of human tissues and body fluids for detection of chemical warfare agent exposures.
- Characterizing the effects of long-term or chronic exposures to chemical warfare agents and/or medical countermeasures to these agents.
- Identifying, exploring, and developing innovative clinical diagnostic, prognostic, and management approaches to nerve agent casualties.
- Developing and validating field-usable procedures for diagnosis, prognosis, and treatment of chemical warfare agent casualties under both field and laboratory conditions.
- Addressing the unique challenges of combined injuries due to both physical trauma from kinetic weapons and exposure to chemical agents. See also, Section II.A.2, Combat Casualty Care Research Program, and Appendix I.II, when research focus is on survival from conventional injuries in a contaminated environment.

VI. Radiation Health Effects Research Program

- A. Medical Countermeasures (MCMs) for Acute Radiation Exposure:** Radiation MCMs include radioprotectants (pre-exposure) and mitigators and therapeutics (post-exposure). Both categories of MCMs are focused on preventing or treating the effects of acute radiation exposure, including the resultant development of acute radiation syndrome (ARS). The focus area examines ARS resulting from exposure to ionizing radiation from radioactive sources or a nuclear detonation, including low linear energy transfer (LET) sources (gamma and X-rays) and high LET sources (neutrons). Research objectives include, but are not limited to, identifying mechanisms of action, obtaining efficacy and safety data in animal models for MCMs for ARS, and demonstrating improved survivability following high doses of radiation with treatment either before exposure or within 24 hours after exposure. Research in biodosimetry in support of MCM development may also be considered.

APPENDIX II: CLINICAL TRIALS

A. Important Aspects of Clinical Trials

A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.

The term “human subjects” is used in this broad agency announcement (BAA) to refer to individuals who will be recruited for or who will participate in the proposed clinical trial. For more information, refer to the Human Research Protection Office (HRPO) website at https://mrdc.amedd.army.mil/index.cfm/collaborate/research_protections/hrpo.

The following are important aspects of submissions proposing a clinical trial:

- The proposed clinical trial is expected to begin no later than 12 months after the award date.
- The proposed intervention to be tested should offer significant potential impact for the targeted population.
- Inclusion of preliminary data relevant to the proposed clinical trial is required.
- The proposed clinical trial must be based on sound scientific rationale that is established through logical reasoning and critical review and analysis of the literature.
- The proposal/application should describe the planned indication for the product label, if appropriate, and include an outline of the development plan required to support that indication.
- The proposal/application should demonstrate availability of, and access to, a suitable patient population that will support a meaningful outcome for the study. The Principal Investigator (PI) should discuss how accrual goals will be achieved and how standards of care may impact the study population.
- The proposal/application should demonstrate documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate. The quality of the product should be commensurate with Food and Drug Administration (FDA) manufacturing standards applicable to the type and phase of product being developed (i.e., Quality System Regulation, Good Manufacturing Practice [GMP]).
- The proposed clinical trial design should include clearly defined and appropriate endpoints, and follow Good Clinical Practice (GCP) guidelines.
- The proposal/application should include a clearly articulated statistical analysis plan, appropriate statistical expertise on the research team, and a power analysis reflecting sample size projections that will clearly answer the objectives of the study.

- The proposal/application should include a clearly articulated data management plan and use of an appropriate database to safeguard and maintain the integrity of the data.
- The proposal/application should include a clearly articulated safety management plan outlining how safety pharmacovigilance will be conducted, as applicable.
- The proposal/application should include a clearly articulated clinical monitoring plan outlining how the study will be monitored for GCP compliance.
- The proposal/application should include a study coordinator(s), who will guide the clinical protocol through the local Investigational Review Board (IRB) of record and other federal agency regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate participant accrual.
- The proposal/application should include a Post-Award Transition Plan (including potential funding and resources) showing how the product will progress to the next clinical trial phase and/or delivery to the market after the successful completion of the award.
- The proposal/application should clearly demonstrate strong institutional support.
- Funded trials are required to post a copy of the IRB-approved informed consent form used to enroll subjects on a publicly available federal website in accordance with federal requirements described in 32 CFR 219.

Funded studies are required to file the study in the National Institutes of Health, National Library of Medicine clinical trials registry, www.clinicaltrials.gov. Refer to the General Submission Instructions, Appendix 1, Section C, for further details.

Multi-Institutional Clinical Trials: If the proposed clinical trial is multi-institutional, plans for the multi-institutional structure governing the research protocol(s) should be outlined in [Attachment 9: Study Personnel and Organization](#). The lead organization responsible for developing the master protocol and master consent form should be identified and should be the single point of contact for regulatory submissions and requirements. In accordance with 32 CFR 219.114, a single IRB or Ethics Committee (EC) pathway is required for any U.S.-based research sites. The master protocol and consent form must be reviewed by the HRPO prior to distribution to the additional sites for IRB/EC review. Communication and data transfer among the collaborating institutions, as well as how specimens and/or imaging products obtained during the study will be handled, should be included in the appropriate sections of the proposal/application. A separate intellectual and material property plan agreed upon by all participating institutions is also required for multi-institutional clinical trials. PIs are encouraged to integrate with existing Department of Defense (DOD) or other government-funded clinical trial networks if appropriate.

B. Full Proposal/Application Submission Components

The Grants.gov submission package includes the following components (refer to the General Submission Instructions, Section III, for additional information on proposal/application submission):

- **SF424 Research & Related Application for Federal Assistance Form:** Refer to the General Submission Instructions, Section III.A.1, for detailed information.

Attachments:

Each attachment to the full proposal/application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines listed in the General Submission Instructions, Appendix 4.

For all attachments, ensure that the file names are consistent with the guidance. Attachments will be rejected if the file names are longer than 50 characters or incorrect file names that contain characters other than the following: A-Z, a-z, 0-9, underscore, hyphen, space, and period. In addition, there are file size limits that may apply in some circumstances. Individual attachments may not exceed 20 MB and the file size for the entire full submission package may not exceed 200 MB.

The Project Narrative is NOT the formal clinical trial protocol. Instead, all essential elements of the proposed clinical trial necessary for scientific review must be included as directed in Attachment 1 (the Project Narrative) and Attachments 6-8 described below. Failure to submit these attachments as part of the application package will result in rejection of the entire application.

- **Attachment 1: Project Narrative (20-page limit): Upload as “ProjectNarrative.pdf”.** The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application.

Describe the proposed project in detail using the outline below.

- **Background:** Describe in detail the rationale for the study. Provide a literature review and describe the preliminary studies and/or preclinical data that led to the development of the proposed clinical trial. Provide a summary of other relevant ongoing, planned, or completed clinical trials and describe how the proposed study differs. Include a discussion of any current clinical use of the intervention under investigation and/or details of its study in clinical trials for other indications (as applicable). The Background section should clearly support the choice of study variables and should explain the basis for the study questions and/or study hypotheses. This section should establish the relevance of the study and explain the applicability of the proposed findings.

If the proposed clinical trial was initiated using other funding prior to this proposal/application, explain the history and background of the clinical trial and declare the source of prior funding. Specifically, identify the portions of the study that will be supported with funds from this award.

- **Objectives/Specific Aims/Hypotheses:** Provide a description of the purpose and objectives of the study with detailed specific aims and/or study questions/hypotheses. The aims should agree with the primary aims and associated tasks described in the Statement of Work (SOW).
- **Study Design:** Describe the type of study to be performed (e.g., prospective, randomized, controlled) and outline the proposed methodology in sufficient detail to show a clear course of action. Describe potential challenges and alternative strategies where appropriate.
 - Identify the intervention to be tested and describe the projected outcomes.
 - Define the study variables, outline why they were chosen, and describe how they will be measured. Include a description of appropriate controls and the endpoints to be tested.
 - Describe the study population and inclusion and exclusion criteria that will be used.
 - Describe the methods that will be used to recruit a sample of human subjects from the accessible population (e.g., convenience, simple random, stratified random).
 - Describe the human subject-to-group assignment process (e.g., randomization, block randomization, stratified randomization, age-matched controls, alternating group, or other procedures), if applicable. Explain the specific actions to accomplish the group assignment (e.g., computer assignment, use of table of random numbers).
 - If using psychometric measures, describe their reliability and validity.
- **Statistical Plan and Data Analysis:** Describe the statistical model and data analysis plan with respect to the study objectives. Specify the approximate number of human subjects to be enrolled. If multiple study sites are involved, state the approximate number to be enrolled at each site. Include a complete power analysis to demonstrate that the sample size is appropriate to meet the objectives of the study. If a subpopulation of a recruited sample population will be used for analysis, complete a statistical analysis to ensure appropriate power can be achieved within the subpopulation study.
- **Attachment 2: Supporting Documentation: Combine and upload as a single file named “Support.pdf”.** Start each document on a new page. If documents are scanned to pdf, the lowest resolution (100 to 150 dpi) should be used. The Supporting Documentation attachment should not include additional information such as figures, tables, graphs, photographs, diagrams, chemical structures, or drawings. These items should be included in the Project Narrative. Any additional material viewed as an extension of the Project Narrative will be removed or may result in administrative withdrawal of the application. ***There are no page limits for any of these components unless otherwise noted.***

- References Cited: List the references cited (including URLs, if available) in the Project Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).
- List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols.
- Facilities, Existing Equipment, and Other Resources: Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether or not government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present government award under which the facilities or equipment items are now accountable. There is no form for this information.
- Publications and/or Patents: Include a list of relevant publication URLs and/or patent abstracts. If publications are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.
- Letters of Organizational Support: Provide a letter (or letters, if applicable), signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project. Letters of support not requested in this BAA, such as those from members of Congress, do not impact application review or funding decisions.
- Letters of Collaboration (if applicable): Provide a signed letter from each collaborating individual or organization that will demonstrate that the PI has the support or resources necessary for the proposed work. If an investigator at a Military Facility is named as a collaborator on a proposal/application, the proposal/application must include a letter from the collaborator's Commander or Commanding Officer at the intramural organization that authorizes the collaborator's involvement.
- Letters of Commitment (if applicable): If the proposed study involves use of a commercially produced investigational drug, device, or biologic, provide a letter of commitment from the commercial entity indicating availability of the product for the duration of the study, support for the proposed phase of research, and support for the indication to be tested.
- Use of DOD Resources (if applicable): Provide a letter of support signed by the lowest-ranking person with approval authority confirming access to active duty military patient populations and/or DOD resources or databases.
- Use of Department of Veterans Affairs (VA) Resources (if applicable): Provide a letter of support from the VA Facility Director(s) or individual designated by the VA Facility Director(s), such as the Associate Chief of Staff for Research and Development (ACOS/R&D) or Clinical Service Chief confirming access to VA

- patients, resources, and/or VA research space. For VA PIs, if the VA NPC is not identified as the applicant institution for administering the funds, include a letter from the VA ACOS/R&D confirming this arrangement and identifying the institution that will administer the funds associated with the proposed research.
- *If the project involves collaboration with a Military Facility, special requirements apply.* A DOD researcher, to include collaborating DOD PIs, must obtain a letter from his/her commanding officer or Military Facility Director authorizing his/her participation in the research project. This letter must be included with the proposal/application.
 - **Joint Sponsorship:** Describe present or prospective joint sponsorship of any portion of the program outlined in the proposal/application. In the absence of agreements between/among sponsors for joint support, the proposal/application should be structured so that the research can be carried out without the resources of any other sponsor. If, however, it is desirable to request partial support from another agency, the proposed plan should be stated and the reasons documented. If the plan cannot be formulated at the time the proposal/application is submitted, information should be sent later as an addendum to the proposal/application. Prior approval from both/all agencies must be secured for research to be undertaken under joint sponsorship. Provide letters of support related to recruitment, subject access, and data access plans.
 - **Intellectual Property:** Information can be found in 2 CFR 200.315, “Intangible Property.”
 - **Intellectual and Material Property Plan (if applicable):** Provide a plan for resolving intellectual and material property issues among participating organizations.
 - **Data and Research Resources Sharing Plan:** Describe how data and resources generated during the performance of the project will be shared with the research community. Refer to the General Submission Instructions, Appendix 2, Section K, for more information about the CDMRP expectations for making data and research resources publicly available.
 - **Attachment 3: Technical Abstract (one-page limit): Upload as “TechAbs.pdf”.** The abstract is vitally important to both the scientific peer and programmatic review processes. In accordance with Section 8123 of the Consolidated and Further Continuing Appropriations Act, 2015 (Public Law 113-235), the PI is required to submit a technical abstract that fully describes the proposed work. The abstract must contain the title of the project and the name of the PI. Do not include figures or tables in the abstract. Use only characters available on a standard QWERTY keyboard. Spell out all Greek or other non-English letters. Abstracts of all funded research projects will be posted publicly. ***Do not include proprietary or confidential information.***

The structured technical abstract should be clear and concise and, at a minimum, provide the following information:

- Background: Provide a brief statement of the ideas and theoretical reasoning behind the proposed work.
 - Objective/Hypothesis: State the objective/hypothesis to be tested. Provide evidence or rationale that supports the objective/hypothesis.
 - Specific Aims: State concisely the specific aims of the study.
 - Study Design: Briefly describe the study design.
 - Relevance: Provide a brief statement explaining the potential relevance of the proposed work to the specific topic area being addressed and its impact on health outcomes.
 - Clinical Impact: Briefly describe how the proposed project will have an impact on research and patient care.
- **Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf”.** The lay abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. *Do not include proprietary or confidential information.* Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

Lay abstracts should be written using the outline below. Do not duplicate the technical abstract.

- Clearly describe the objectives and rationale for the proposed study in a manner readily understood by readers without a background in science or medicine.
 - Describe the ultimate applicability and impact of the research.
 - What types of patients will it help, and how will it help them? Include the current available statistics to the related injury/condition.
 - What are the potential clinical applications, benefits, and risks?
 - What is the projected timeline it may take to achieve the expected patient-related outcome?
 - Describe how the proposed project will benefit Service Members, Veterans, and/or their family members.
- **Attachment 5: Statement of Work (three-page limit): Upload as “SOW.pdf”.** The SOW outlines and establishes the performance expectations and milestones for which the U.S. Army Medical Research and Development Command (USAMRDC) may provide

funding. The SOW will be incorporated into the award document and, as such, is subject to release under the Freedom of Information Act. The SOW should identify all collaborating research sites involved in the performance of the research. Suggested SOW formats and examples specific to different types of research projects are available on the electronic Biomedical Research Application Portal (eBRAP) “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>).

A series of relatively short statements should be included that comprise the approach to each of the major goals or objectives of the proposed research. The statements should outline the specific tasks, systems, key assessments/techniques, and materials that are reasonable estimates for testing the proposed hypotheses of the study. A timeline should be included that shows the work statements to be accomplished in each year of the award. Any animal use and/or human subjects recruitment should be included. Allow at least 2 to 3 months for the USAMRDC Office of Research Protections (ORP) regulatory review and approval processes for studies involving human subjects and 2 to 3 months for studies involving animal subjects.

If applicable, indicate timelines required for regulatory approvals relevant to human subjects research (e.g., Investigational New Drug (IND) and Investigational Device Exemption (IDE) applications) by the FDA or other government agency.

- **Attachment 6: Human Subject Recruitment and Safety Procedures (no page limit): Upload as “HumSubProc.pdf”.** The Human Subject Recruitment and Safety Procedures attachment should include the components listed below.
 - **Study Population:** Describe the target population (to whom the study findings will be generalized) and the nature, approximate number, and pertinent demographic characteristics of the accessible population at the study site(s) (population from whom the sample will be recruited/drawn). Provide a table of anticipated enrollment counts at each study site. Demonstrate that the research team has access to the proposed study population. Furthermore, discuss past efforts in recruiting human subjects from the target population for previous clinical trials (if applicable). Address any potential barriers to accrual and plans for addressing unanticipated delays, including a mitigation plan for slow or low enrollment or poor retention. Provide justification related to the scientific goals of the proposed study for limiting inclusion of any group by age, race, ethnicity, or sex/gender.
 - **Inclusion/Exclusion Criteria:** List the inclusion and exclusion criteria for the proposed clinical trial. Inclusion/exclusion criteria should take into consideration the specific risk profile of the studies to be conducted and the standard of care for that patient population. Provide detailed justification for exclusions.
 - ***Inclusion of Women and Minorities in Study:*** Consistent with the Belmont Report, “Ethical Principles and Guidelines for the Protection of Human Subjects,” and congressional legislation, special attention is given to inclusion of women and/or minorities in studies funded or supported by the USAMRDC. This policy is intended to promote equity both in assuming the burdens and in receiving the benefits of

- human subjects research. Describe the strategy for the inclusion of women and minorities in the clinical trial appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex/gender, race, and ethnicity, and an accompanying rationale for the selection of subjects. Provide an anticipated enrollment table(s) with the proposed enrollment distributed on the basis of sex/gender, race, and ethnicity. The suggested Inclusion Enrollment Report format is a one-page fillable PDF form, which can be downloaded from eBRAP at <https://ebrap.org/eBRAP/public/Program.htm>.
- **Description of the Recruitment Process:** Explain methods for identification of potential human subjects (e.g., medical record review, obtaining sampling lists, healthcare provider identification).
 - Describe the recruitment process in detail. Address who will identify potential human subjects, who will recruit them, and what methods will be used to recruit them.
 - If human subjects will be compensated for participation in the study, include a detailed description of and justification for the compensation plan.
 - Describe the recruitment and advertisement materials. The recruitment materials should not be coercive or offer undue inducements and should accurately reflect the study.
 - **Description of the Informed Consent Process:** Specifically describe the plan for obtaining informed consent from human subjects.
 - *For the proposed clinical trial, provide a draft, in English, of the Informed Consent Form.*
 - Identify who is responsible for explaining the study, answering questions, and obtaining informed consent. Include a plan for ensuring that human subjects' questions will be addressed during the consent process and throughout the trial.
 - Include information regarding the timing and location of the consent process.
 - Address issues relevant to the mental capacity of the potential human subject (e.g., altered capacity due to administration of any mind-altering substances such as tranquilizers, conscious sedation or anesthesia, brain injury, stress/life situations, or human subject age), if applicable.
 - Address how privacy and time for decision-making will be provided and whether or not the potential human subject will be allowed to discuss the study with anyone before making a decision.
 - Consider the need for obtaining ongoing consent or for re-assessing capacity over the course of a long-term study and describe any relevant procedures to assure continued consent.

- Describe the plan for the consent of the individual’s Legally Authorized Representative (LAR) to be obtained prior to the human subject’s participation in the study. State law defines who may act as the LAR. The local IRB of record should be consulted for guidance regarding who can serve as LAR for research at the study site. *Note:* The PI must describe a clear intent to benefit for human subjects who cannot give their own consent to participate in the proposed clinical trial to be in compliance with 10 USC 980 (<https://www.gpo.gov/fdsys/pkg/USCODE-2011-title10/pdf/USCODE-2011-title10-subtitleA-partII-chap49-sec980.pdf>).
 - *Assent:* If minors or other populations that cannot provide informed consent are included in the proposed clinical trial, a plan to obtain assent (agreement) from those with capacity to provide it, or a justification for a waiver of assent, should be provided. PIs should consult with their local IRB to identify the conditions necessary for obtaining assent.
- **Screening Procedures:** List and describe any evaluations (e.g., laboratory procedures, history, or physical examination) that are required to determine eligibility/suitability for study participation and the diagnostic criteria for entry. Please note that some screening procedures may require a separate consent or a two-stage consent process. Informed consent must be obtained prior to initiation of any procedures for the purpose of determining eligibility.
- **Risks/Benefits Assessment:**
- **Foreseeable risks:** Clearly identify all study risks, including potential safety concerns and adverse events. Study risks include any risks that the human subject is subjected to as a result of participation in the clinical trial. Consider psychological, legal, social, and economic risks as well as physical risks. If the risks are unknown, this should be stated. If applicable, any potential risk to the study personnel should be identified.
 - **Risk management and emergency response:**
 - ❖ Describe how safety surveillance and reporting to the IRB and FDA (if applicable) will be managed and conducted.
 - ❖ Describe all safety measures to minimize and/or eliminate risks to human subjects and study personnel or to manage unpreventable risks. Include safeguards and planned responses such as dose reduction or stopping criteria based on toxicity grading scales or other predetermined alert values.
 - ❖ Discuss the overall plan for provision of emergency care or treatment for an adverse event for study-related injuries, to include who will be responsible for the cost of such care.

- ❖ Address any special precautions to be taken by the human subjects before, during, and after the study (e.g., medication washout periods, dietary restrictions, hydration, fasting, pregnancy prevention).
- ❖ Describe any special care (e.g., wound dressing assistance, transportation due to side effects of study intervention impairing ability to drive) or equipment (e.g., thermometers, telemedicine equipment) needed for human subjects enrolled in the study.
- **Potential benefits:** Describe known and potential benefits of the study to the human subject, a specific community, or society. Articulate the importance of the knowledge to be gained as a result of the proposed research. Discuss why the potential risks to human subjects are reasonable in relation to the anticipated benefits to the human subjects and others that may be expected to result.
- **Attachment 7: Intervention (no page limit): Upload as “Intervention.pdf”.** The Intervention attachment should include the components listed below.
 - **Description of the Intervention:** Identify the intervention to be tested and describe the particular outcomes. As applicable, the description of the intervention should include the following components: complete name and composition, storage and handling information, source, dose, schedule, administration route, washout period, duration of the intervention, and concomitant medications allowed. Description of devices should include general concept of design, detailed operational instructions, any potential risks to users, and intended benefits. Other types of interventions should be fully described. Indicate who holds the intellectual property rights to the intervention, if applicable, and how the PI has obtained access to those rights for the conduct of the clinical trial.

Summarize key preclinical pharmacological findings, dosage studies, and other clinical studies (if applicable) that examine the safety of the intervention.

- **Study Procedures:** Describe the interaction with the human subject to include the study intervention that he/she will experience. Provide sufficient detail in chronological order for a person uninvolved in the study to understand what the human subject will experience. Provide a schedule (e.g., flowchart or diagram) of study evaluations and follow-up procedures. Discuss how compliance with Good Laboratory Practice (GLP), GMP, GCP, and other regulatory considerations will be established, monitored, and maintained, as applicable.
- **Clinical Monitoring Plan:** Describe how the study will be conducted by and monitored for ICH E6 (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) GCP compliance, by an independent clinical trial monitor (or clinical research associate). The monitoring plan should describe the types of monitoring visits to be conducted, the intervals (based on level of risk), how corrective actions will be reported to the

Sponsor and PI, and how they will be corrected and prevented by the clinical trial site/PI.

- **Attachment 8: Data Management (no page limit): Upload as “Data_Manage.pdf”.** The Data Management attachment should include the components listed below.
 - **Data Management:** Describe all methods used for data collection to include the following:
 - **Identifiers:** Describe the unique identifiers or specific code system to be used to identify human subjects, if applicable.
 - **Confidentiality:**
 - ❖ Explain measures taken to protect the privacy of human subjects and maintain confidentiality of study data. Strategies to protect the privacy and confidentiality of study records, particularly those containing identifying information, should be addressed.
 - ❖ Address who will have access to study records, data, and specimens, including an acknowledgment that representatives of the DOD are eligible to review study records.
 - ❖ Address requirements for reporting sensitive information to state or local authorities.
 - **Data capture, verification, and disposition:** Describe how data will be captured and verified. Describe where data (both electronic and hard copy) will be stored, who will keep the data, how the data will be stored, the process for locking the database at study completion, and the length of time data will be stored. Describe the proposed database, how it will be developed and validated, and its capability to safeguard and maintain the integrity of the data. Describe the database lock process. For FDA-regulated studies, compliance with 21 CFR 11 and appropriate data standards (such as those established by the Clinical Data Interchange Standards Consortium) is required.
 - **Sharing study results:** In cases where the human subject could possibly benefit medically or otherwise from the information, explain whether or not the results of screening and/or study participation will be shared with human subjects or their primary care provider, to include results from any screening or diagnostic tests performed as part of the study.
 - **Laboratory Evaluations:**
 - **Specimens to be collected, schedule, and amount:** All specimens that will be collected for study purposes must be clearly stated. The collection schedule and amount of material collected must also be clearly described.

- **Evaluations to be made:** Describe all evaluations that will be made for study purposes. Explain how the results of laboratory evaluations will be used to meet the objectives of the study (or to monitor safety of human subjects).
 - **Storage:** Describe specimen storage, to include location of storage, how long specimens will be stored, any special conditions required, labeling, and specimen disposition. Outline the plan to store specimens for future use to include considerations for informed consent and providing human subjects with an opportunity to decline participation in the study.
 - **Laboratories performing evaluations and special precautions:** Identify the laboratory performing each evaluation, as well as any special precautions that should be taken in handling the samples. Special precautions that should be taken by the human subject before, during, or after the laboratory procedure should be clearly defined. If transport of samples is required, describe provisions for ensuring proper storage during transport.
- **Attachment 9: Study Personnel and Organization (no page limit):** Start each document on a new page. **Combine into one document and upload as “Personnel.pdf”.** The Study Personnel and Organization attachment should include the components listed below.
- **Organizational Chart:** Provide an organizational chart that identifies key members of the study team and provides an outline of the governing structure for multi-institutional studies. Identify collaborating organizations, centers, and/or departments and name each person’s position on the project. Identify the data and clinical coordinating center(s) and note any involvement from Contract Research Organizations, as appropriate. If applicable, identify the FDA regulatory sponsor and any external consultants or other experts who will assist with FDA applications. While there is no specified format for this information, a table(s) or diagram is recommended.
 - **Study Personnel Description:** Briefly describe the roles of the individuals listed in the organizational chart on the project. Describe relevant experience and qualifications that demonstrate appropriate expertise for the given role. An external research monitor (if applicable) and study coordinator(s) should be included.
 - **Study Management Plan:** Provide a plan for ensuring the standardization of procedures among staff and across sites (if applicable). If the proposed clinical trial is multi-institutional, clearly describe the multi-institutional structure governing the research protocol(s) across all participating institutions. Provide a regulatory submission plan for the master protocol and master consent form by the lead organization; include a single IRB/EC review for all U.S.-based research sites. If applicable, describe how communication and data transfer between the collaborating institutions will occur, as well as how data, specimens, and/or imaging products obtained during the study will be handled and shared.

- **Attachment 10: Research Data Collection Instruments, if applicable (no page limit): Upload as “Data_Collection.pdf”.** The Research Data Collection Instruments attachment should include a copy of the most recent version of questionnaires, data collection forms, rating scales, interview guides, or other instruments. For each instrument, describe how the information collected is related to the objectives of the study. Describe how and when the instrument(s) will be administered. Describe how the instrument(s) will be adapted to the subject population, if applicable. If the adaptation results in a deviation from validated instruments, please justify.
- **Attachment 11: Impact and Relevance to Military Health Statement (three-page limit): Upload as “Impact.pdf”.**
 - Identify the volunteer population(s) that will participate in the proposed intervention, describe how they represent the target population that would benefit from the intervention, and describe the potential impact of the proposed clinical trial on the outcomes of individuals with the targeted disease or condition.
 - ***Describe the short-term impact:*** Detail the anticipated outcomes that will be directly attributed to the results of the proposed clinical trial.
 - ***Describe the long-term impact:*** Explain the long-range vision for implementation of the intervention in the clinic or field, and describe the anticipated long-term benefits for the targeted population.
 - Describe any relevant controversies or treatment issues that will be addressed by the proposed clinical trial.
 - Describe any potential issues that might limit the impact of the proposed clinical trial and strategies that may be employed to overcome those issues.
 - Describe how the intervention represents an improvement over currently available interventions and/or standards of care.
 - Describe how the proposed study is responsive to the healthcare needs of military Service Members, Veterans, and/or beneficiaries. Provide information about the incidence and/or prevalence of the disease or condition in the general population as well as in military Service Members, Veterans, and/or beneficiaries.
 - If active duty military, military families, and/or Veteran population(s) will be used in the proposed research project, describe the population(s) and the appropriateness of the population(s) for the proposed study. If a non-military population will be used for the proposed research project, explain how the population simulates the targeted population (i.e., military Service Members, Veterans, and/or beneficiaries).
 - If applicable, show how the proposed research project aligns with DOD and VA areas of research interests. Provide a description of how the knowledge or technology gained from the research could be implemented in a dual-use capacity to benefit the civilian population and address a military need, as appropriate.

- **Attachment 12: Post-Award Transition Plan (two-page limit): Upload as “Transition.pdf”.** Describe/discuss the methods and strategies proposed to move the intervention to the next phase of development (clinical trials, commercialization, and/or delivery to the civilian or military market) after successful completion of the award. Applicants are encouraged to work with their organization’s Technology Transfer Office (or equivalent) to develop the transition plan. PIs are encouraged to explore developing relationships with industry and/or other funding agencies to facilitate moving the product into the next phase of development. The post-award transition plan should include the components listed below.
 - The planned indication for the product label, if appropriate, and an outline of the development plan required to support that indication. Describe in detail the FDA regulatory strategy, to include considerations for compliance with GMP, GLP, and GCP (if appropriate).
 - Using Appendix VI as a guide, describe the maturity of the product and provide the current and projected research technology or knowledge readiness level (as appropriate) at the end of the proposed project or knowledge outcome.
 - A description of the scientific or technical requirements needed to advance the research findings. Include steps necessary for FDA regulatory approval for the planning indication, and compliance with GMP, GLP, and GCP guidelines as appropriate.
 - Details of the funding strategy to transition to the next level of development and/or commercialization (e.g., partners, internal/external funding opportunities to be applied for). Include a description of collaborations and other resources that will be used to provide continuity of development.
 - For Knowledge Products, a description of collaborations and other resources that will be used to provide continuity of development including proposed development or modification of Clinical Practice Guidelines (CPG) and recommendations, provider training materials, patient brochures, and other clinical support tools, scientific journal publications, models, simulations, and applications. A “Knowledge Product” is a non-material product that addresses an identified need, topic area, or capability gap, is based on current evidence and research, aims to transition into medical practice, training, tools, or to support material solutions (systems to develop, acquire, provide, and sustain medical solutions and capabilities), and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.
 - A timeline with defined milestones and deliverables describing the expected post-award progress of the results toward the next phase of development and eventual clinical impact.

- Ownership rights/access to the intellectual property necessary for the development and/or commercialization of products or technologies supported with this award and the government’s ability to access such products or technologies in the future.
- A risk analysis for cost, schedule, manufacturability, and sustainability.
- **Attachment 13: Regulatory Strategy (no page limit): If submitting multiple documents, start each document on a new page. Combine and upload as a single file named “Regulatory.pdf”.** Provide the information requested below and provide supporting documentation as applicable.
 - State the product/intervention name.

For products/interventions that do not require regulation by the FDA or an international regulatory agency:

- Explain why the product/intervention is exempt from FDA oversight. Provide confirmation that the proposed study does not require regulation by the FDA in writing from the IRB of record or the FDA. If the proposed study will be conducted at international sites, provide equivalent information relevant to the host country(ies) regulatory requirements. No further information for this attachment is required.

For products/interventions that require regulation by the FDA and/or an international regulatory agency:

- State whether the product is FDA-approved, -licensed, or -cleared, and marketed in the United States.
- If the product is marketed in the United States, state the product label indication. State whether the proposed research involves a change to the approved label indication for the route of administration, dosage level, and/or subject population. Indicate whether the proposed research involves a change that increases the risks associated with using the product. State whether the product is being promoted for an off-label use (where promotion involves the sale of a marketed product).
- If the product is not currently FDA-approved, -licensed, or -cleared, state the planned indication/use. Indicate whether the product would be classified as a drug, device, biologic, or combination product. Indicate whether the FDA has confirmed the proposed classification. Identify the regulatory sponsor. Include a signed sponsor commitment letter acknowledging the regulatory sponsor’s understanding of all sponsor responsibilities and commitment to oversee execution of the study.
- For the BAA, if an IND or IDE is required to initiate the proposed research project, it must be submitted to the FDA prior to submission of the full proposal/application. The IND or IDE should be specific for the investigational product (i.e., not a derivative or alternate version of the product) and indication to be tested in the proposed pilot clinical trial. Provide the date of submission, application number, and sponsor for any existing FDA applications in place. If there are any existing cross-

- references in place, provide the application number and associated sponsor. Provide an explanation of the status of the application (e.g., past the critical 30-day period, pending response to questions raised by the FDA, on clinical hold). Provide a summary of previous meetings with the FDA on development of this product, if appropriate. A copy of the Agency meeting minutes should be included if available. Provide copies of communications from the FDA relevant to the most recent status of the IND or IDE application.
- If an IND or IDE has already been obtained for the investigational product, provide a copy of the acceptance from the FDA.
 - Provide the current status for manufacturing development (e.g., manufacturer’s name, GMP-compliant lots available, status of stability testing, etc.), non-clinical development (e.g., test facility name, status of pivotal GLP toxicology studies to support phase 1 testing), and clinical development (e.g., clinical site name, safety profile, status of any completed or ongoing clinical trials).
 - Describe the overall regulatory strategy and product development plan that will support the planned product indication. Include a description of the numbers and types of studies proposed to reach approval, licensure, or clearance, the types of FDA meetings that will be held/planned, and the submission filing strategy. Include considerations for compliance with current GMP, GLP, and GCP guidelines.
- **Attachment 14: Representations: Upload as “RequiredReps.pdf”.** All extramural applicants must complete and submit the Required Representations template available on eBRAP (<https://ebrap.org/eBRAP/public/Program.htm>). For more information, see the General Submission Instructions, Appendix 5, Section B, Representations.
 - **Attachment 15: Suggested Collaborating DOD Military Facility Budget Format, if applicable: Upload as “MFBudget.pdf”.** If a Military Facility (MHS facility, research laboratory, medical treatment facility, dental treatment facility, or a DOD activity embedded with a civilian medical center) will be a collaborator in performance of the project, complete a separate budget using “Suggested Collaborating DOD Military Facility Budget Format,” available for download on the eBRAP “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>), including a budget justification, for each Military Facility as instructed. The costs per year should be included on the Grants.gov Research & Related Budget Form under subaward costs. Refer to the General Submission Instructions, Section III.A.8., for detailed information.

To evaluate compliance with Title IX of the Education Amendments of 1972 (20 USC 1681(a) et seq.), the DOD is collecting certain demographic and career information to be able to assess the success rates of women who are proposed for key roles in applications in science, technology, engineering, or mathematics (STEM) disciplines. To enable this assessment, each proposal/application must include the following forms completed as indicated.

Research & Related Personal Data: Refer to the General Submission Instructions, Section III.A.3, for detailed information.

Research & Related Senior/Key Person Profile (Expanded): Refer to the General Submission Instructions, Section III.A.4, for detailed information.

- PI Biographical Sketch (five-page limit): Upload as “Biosketch_LastName.pdf.” The suggested biographical sketch format is available on the “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>) in eBRAP. The National Institutes of Health (NIH) Biographical Sketch may also be used. All biographical sketches should be submitted in uneditable PDF format.
- PI Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf.”
- Key Personnel Biographical Sketches (five-page limit each): Upload as “Biosketch_LastName.pdf.”
- Key Personnel Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf.”

Research & Related Budget: Refer to the General Submission Instructions, Section III.A.5, for detailed information.

Budget Justification (no page limit): Upload as “BudgetJustification.pdf”. The budget justification for the entire period of performance must be uploaded to the Research & Related Budget after completion of the budget for Period 1.

Project/Performance Site Location(s) Form: Refer to the General Submission Instructions, Section III.A.6, for detailed information.

Research & Related Subaward Budget Attachment(s) Form (if applicable): Refer to the General Submission Instructions, Section III.A.7, for detailed information.

NOTE: Proposals/applications from **federal agencies** must include in their budget justifications a **Federal Financial Plan**. Proposals/applications from organizations that include **collaborations with DOD Military Facilities** must comply with special requirements. Refer to the General Submission Instructions, Section III.A.5, “Research & Related Budget,” for detailed information.

C. Review Criteria for Research Proposals/Applications Including a Clinical Trial

Peer Review: To determine technical merit, all proposals/applications will be evaluated according to the following scored criteria, which are listed in descending order of importance:

- **Clinical Impact**
 - How relevant the anticipated outcomes of the proposed clinical trial are to the targeted population.
 - How well the sample population represents the targeted patient population that might benefit from the proposed intervention.
 - How the potential outcomes of the proposed clinical trial will provide/improve short-term benefits for individuals.
 - How significantly the long-term benefits for implementation of the intervention may impact patient care and/or quality of life.
- **Research Strategy**
 - How well the scientific rationale for testing the intervention is supported by the preliminary data, critical review and analysis of the literature, and/or laboratory/preclinical evidence.
 - How well the study aims, hypotheses or objectives, experimental design, methods, data collection procedures, and analyses are designed to answer clearly the clinical objective.
 - How well the inclusion and randomization criteria meet the needs of the proposed clinical trial.
 - How well the exclusion criteria are justified.
 - How well plans to collect specimens and conduct laboratory evaluations are addressed, if applicable.
 - To what degree the data collection instruments, if applicable, are appropriate to the proposed study.
- **Statistical Plan**
 - To what degree the statistical model and data analysis plan are suitable for the planned study.
 - How the statistical plan, including sample size projections and power analysis, is adequate for the study and all proposed correlative studies.

- Whether the statistical plan compensates for the use of a subpopulation of a recruited sample population to ensure appropriate power can be achieved within the subpopulation study.
- **Intervention**
 - Whether there is evidence of support, indicating availability of the intervention from its source, for the duration of the proposed clinical trial (if applicable).
 - To what degree the intervention addresses the clinical need(s) described.
 - How the intervention compares with currently available interventions and/or standards of care.
 - To what degree preclinical and/or clinical evidence supporting the safety of the intervention is provided.
 - Whether a member of the study team holds the IND/IDE for the indication proposed or whether the timeline proposed for obtaining the IND/IDE is appropriate (if applicable).
 - For investigator-sponsored INDs, whether there is evidence of appropriate institutional support, including capabilities to ensure monitoring as required by the FDA.
 - Whether plans to comply with GMP, GLP, and GCP guidelines are appropriate.
 - Whether measures are described to ensure the consistency of dosing of active ingredients for nutritional supplements (if applicable).
- **Recruitment, Accrual, and Feasibility**
 - How well the availability of human subjects for the clinical trial and the prospect of their participation is addressed.
 - Whether access to the proposed human subjects population is demonstrated.
 - The degree to which the recruitment, informed consent, screening, and retention processes for human subjects will meet the needs of the proposed clinical trial.
 - How well the proposal/application identifies possible delays (e.g., slow accrual, attrition) and presents adequate contingency plans to resolve them.
 - To what extent the proposed clinical trial might affect the daily lives of the individual human subjects participating in the study (e.g., will human subjects still be able to take their regular medications while participating in the clinical trial? Are human subjects required to stay overnight in a hospital?).

- **Ethical Considerations**

- How the level of risk to human subjects is minimized and how the safety monitoring and reporting plan is appropriate for the level of risk.
- How well the evidence shows that the procedures are consistent with sound research design and, when appropriate, that these procedures are already in use for diagnostic or treatment purposes.
- To what degree confidentiality and privacy issues are appropriately considered.
- To what degree the process for seeking informed consent is appropriate and whether safeguards are in place for vulnerable populations.

- **Personnel and Communication**

- Whether the composition of the study team (e.g., study coordinator, statistician) is appropriate.
- To what degree the study team's background and expertise are appropriate to accomplish the proposed work (e.g., statistical expertise, expertise in the disease, and clinical studies).
- How the levels of effort of the study team members are appropriate for successful conduct of the proposed trial.
- How well the logistical aspects of the proposed clinical trial (e.g., communication plan, data transfer and management, standardization of procedures) meet the needs of the proposed clinical trial.

- **Transition Plan and Regulatory Strategy**

- Whether the identified next level of development and/or commercialization is realistic.
- Whether the application appropriately addresses available opportunities and potential barriers that could impact the progress of commercializing and/or translating the study results into clinical practice.
- Whether the funding strategy described to bring the intervention to the next level of development (e.g., specific industry partners, specific funding opportunities to be applied for) is reasonable and realistic.
- How the regulatory strategy and development plan to support a product label change, if applicable, is appropriate and well described.
- Whether the proposed collaborations and other resources for providing continuity of development, including proposed development or modification of CPG and recommendations, provider training materials, patient brochures, and other clinical

support tools, scientific journal publications, models, simulations, and applications are established and/or achievable.

- Whether the timeline for expected post-award progress is reasonable and contains appropriate milestones and deliverables for advancing the study results toward clinical impact.
 - Whether the potential risk analysis for cost, schedule, manufacturability, and sustainability is realistic and reasonable.
 - How well the proposal/application identifies intellectual property ownership, describes any appropriate intellectual and material property plan among participating organizations (if applicable), and addresses any impact of intellectual property issues on product development and subsequent government access to products supported by this BAA/Funding Opportunity.
 - Whether the applicant has demonstrated that they have access to all intellectual property rights necessary for development and commercialization and evidence that the government has the ability to access such products or technologies.
- **Budget**
 - Whether the budget is appropriate for the proposed research.
 - **Environment**
 - To what degree the scientific environment, clinical setting, and accessibility of institutional resources support the clinical trial at each participating center or institution (including collaborative arrangements).
 - Whether there is evidence for appropriate institutional commitment from each participating institution.
 - If applicable, to what degree the intellectual and material property plan is appropriate.
 - **Programmatic Review:** To make funding recommendations, the following criteria will be used by programmatic reviewers:
 - Scientific peer review results
 - Adherence to the intent of the award mechanism
 - Program portfolio composition and priorities
 - Relative military benefit
 - Relative innovation, impact, and translatability

NOTE: Military-relevant research must be responsive to the healthcare needs of the Armed Forces, family members of the Armed Forces, and the U.S. Veteran population. Proposals/ applications must address a military-relevant health problem responsive to one of the Research Areas of Interest identified in [Section II.A](#) and [Appendix I](#).

D. Checklist for Research Proposal/Application Submission Including a Clinical Trial

Application Components	Action	Completed
SF424 (R&R) Application for Federal Assistance	Complete form as instructed.	
Attachments	Project Narrative: Upload as Attachment 1 with file name "ProjectNarrative.pdf"	
	Supporting Documentation: Upload as Attachment 2 with file name "Support.pdf"	
	Technical Abstract: Upload as Attachment 3 with file name "TechAbs.pdf"	
	Lay Abstract: Upload as Attachment 4 with file name "LayAbs.pdf"	
	Statement of Work: Upload as Attachment 5 with file name "SOW.pdf"	
	Human Subject Recruitment and Safety Procedures: Upload as Attachment 6 with file name "HumSubProc.pdf"	
	Intervention: Upload as Attachment 7 with file name "Intervention.pdf"	
	Data Management: Upload as Attachment 8 with file name "Data_Manage.pdf"	
	Study Personnel and Organization: Upload as Attachment 9 with file name "Personnel.pdf"	
	Research Data Collection Instruments: Upload as Attachment 10 with file name "Data_Collection.pdf," if applicable	
	Impact and Relevance to Military Health Statement: Upload as Attachment 11 with file name "Impact.pdf"	
	Post-Award Transition Plan: Upload as Attachment 12 with file name "Transition.pdf"	
	Regulatory Strategy: Upload as Attachment 13 with file name "Regulatory.pdf"	
	Representations: Upload as Attachment 14 with file name "RequiredReps.pdf"	
DOD Military Budget Form(s): Upload as Attachment 15 with file name "MFBudget.pdf" if applicable		
Research & Related Personal Data	Complete form as instructed.	

Application Components	Action	Completed
Research & Related Senior/Key Person Profile (Expanded)	Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field.	
	Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field.	
	Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field.	
	Attach Previous/Current/Pending (Support_LastName.pdf) for each senior/key person to the appropriate field.	
Research & Related Budget	Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field.	
Project/Performance Site Location(s) Form	Complete form as instructed.	
Research & Related Subaward Budget Attachment(s) Form, if applicable	Complete form as instructed.	

APPENDIX III: DOD AND VA WEBSITES

PIs are encouraged to integrate and/or align their research projects with DOD and/or VA research laboratories and programs. Collaboration with DOD or VA investigators is also encouraged. Below is a list of websites that may be useful in identifying additional information about DOD and VA areas of research interest, ongoing research, or potential opportunities for collaboration.

Air Force Office of Scientific Research
<https://www.wpafb.af.mil/afri/afosr/>

Air Force Research Laboratory
<https://www.wpafb.af.mil/afri/>

Armed Forces Radiobiology Research
Institute
<https://www.usuhs.edu/afri/>

Combat Casualty Care Research Program
<https://ccc.amedd.army.mil>

Congressionally Directed Medical Research
Programs
<https://cdmrp.army.mil>

Defense Advanced Research Projects
Agency
<https://www.darpa.mil/>

Defense Health Agency
<https://health.mil/dha>

Defense Technical Information Center
<https://www.dtic.mil>

Defense Threat Reduction Agency
<https://www.dtra.mil/>

Military Health System Research
Symposium
<https://www.mhsrs.net/>

Military Infectious Diseases Research
Program
<https://midrp.amedd.army.mil>

Military Operational Medicine Research
Program
<https://momrp.amedd.army.mil>

Naval Health Research Center
<https://www.med.navy.mil/Naval-Medical-Research-Center/Naval-Health-Research-Center/>

Navy Bureau of Medicine and Surgery
<https://www.med.navy.mil/>

Naval Medical Research Center
<https://www.med.navy.mil/Naval-Medical-Research-Center/>

Navy and Marine Corps Public Health
Center
<https://www.med.navy.mil/Navy-Marine-Corps-Public-Health-Center>

Office of Naval Research
<https://www.onr.navy.mil/>

Office of the Under Secretary of Defense for
Acquisition, Technology and Logistics
<https://www.acq.osd.mil/>

Telemedicine and Advanced Technology
Research Center
<https://www.tatrc.org/>

Uniformed Services University of the Health
Sciences
<https://www.usuhs.edu/research>

U.S. Air Force 59th Medical Wing
<https://www.59mdw.af.mil>

U.S. Army Aeromedical Research
Laboratory
<https://www.usaarl.army.mil>

U.S. Army Combat Capabilities
Development Command
<https://www.army.mil/ccdc>

U.S. Army Institute of Surgical Research
<https://www.usaisr.amedd.army.mil/>

U.S. Army Medical Research and
Development Command
<https://mrdc.amedd.army.mil>

U.S. Army Medical Research Institute of
Infectious Diseases
<https://www.usamriid.army.mil/>

U.S. Army Research Institute of
Environmental Medicine
<https://www.usariem.army.mil/>

U.S. Army Research Institute for Behavioral
and Social Sciences
<https://ari.altess.army.mil/>

U.S. Army Research Laboratory
<https://www.arl.army.mil>

U.S. Army Sharp, Ready & Resilient
Directorate
<https://www.armyresilience.army.mil/sharp/index.html>

U.S. Department of Defense Blast Injury
Research Program
<https://blastinjuryresearch.amedd.army.mil/>

U.S. Department of Veterans Affairs, Office
of Research and Development
<https://www.research.va.gov>

U.S. Naval Research Laboratory
<https://www.nrl.navy.mil>

Walter Reed Army Institute of Research
<https://www.wrair.army.mil/>

APPENDIX IV: PROCEDURES FOR ACQUISITION, PROCESSING, STORAGE, AND SHIPMENT OF BIO-FLUIDS

The following pre-analytical variables should be recorded when collecting bio-fluids:

- Time of sample collection
- Time of sample freezing and the interval between collection and freezing
- Temperature of freeze
- Needle size and type (21 G preferred)
- Tube collection order
- Tube labels
- Centrifugation parameters
- Handling, shipping, and storage temperature
- Tube handling
- Small aliquot size
- Sample storage quality control

The following subject characteristics should be recorded when collecting bio-fluids:

- Fasting and diet
- Therapy
- Time of day
- Physical activity
- Acute state (rested?)
- Body position

APPENDIX V: NATIONAL INSTITUTE OF MENTAL HEALTH DATA ARCHIVE — INFORMED CONSENT

Psychological Health, Human Subjects Studies Informed Consent and Data Repository

Data from this study may be submitted to the National Institute of Mental Health Data Archive (NDA). NDA is a data repository run by the National Institute of Mental Health (NIMH) that allows researchers studying mental illness to collect and share deidentified information with each other. A data repository is a large database where information from many studies is stored and managed. Deidentified information means that all personal information about research participants such as name, address, and phone number is removed and replaced with a code number. With an easier way to share, researchers hope to learn new and important things about mental illnesses more quickly than before.

During and after the study, the researchers will send deidentified information about your health and behavior and in some cases, your genetic information, to NDA. Other researchers nationwide can then file an application with the NIMH to obtain access to your deidentified study data for research purposes. Experts at the NIMH who know how to protect health and science information will look at every request carefully to minimize risks to your privacy.


You may not benefit directly from allowing your information to be shared with NDA. The information provided to NDA may help researchers around the world treat future children and adults with mental illnesses so that they have better outcomes. NIMH will also report to Congress and on its website about the different studies that researchers are conducting using NDA data. However, you will not be contacted directly about the data you contributed to NDA.

You may decide now or later that you do not want to share your information using NDA. If so, contact the researchers who conducted this study, and they will tell NDA, which can stop sharing the research information. However, NDA cannot take back information that was shared before you changed your mind. If you would like more information about NDA, this is available on-line at <https://data-archive.nimh.nih.gov>.

APPENDIX VI: TECHNOLOGY READINESS LEVELS AND KNOWLEDGE READINESS LEVELS

Technology Readiness Levels (TRLs): TRLs are used to categorize the product maturity of materiel solutions. The Department of Defense (DOD) Technology Readiness Assessment (TRA) Deskbook, is a reference for systematic assessment of technical maturity of relevant materiel solutions. For biomedical applications, Biomedical TRL definitions and descriptions have been developed which account for regulatory context for technology maturity and *intended context of use*. Information on Biomedical TRLs can be found in Appendix E of the DOD TRA Deskbook (July 2009, <https://apps.dtic.mil/docs/citations/ADA524200>).

Knowledge Readiness Levels (KRLs): The scientific maturity of knowledge products resulting from biomedical research are not assessed in the same manner as materiel solutions. At the request of the U.S. Army Medical Research and Development Command, the Rand Corporation developed and released a framework to assess the relative scientific maturity of knowledge products. This process is described in a 2019 Rand Corporation Report (https://www.rand.org/pubs/research_reports/RR2127.html). The figures below represent a quick reference guide for assessing KRLs for knowledge products.



APPENDIX VII: ACRONYMS AND ABBREVIATIONS

ACOS/R&D	Associate Chief of Staff for Research and Development
AFARS	Army Federal Acquisition Regulation Supplement
ARRIVE	Animal Research: Reporting <i>In Vivo</i> Experiments
AR	Army Regulation
ARS	Acute Radiation Syndrome
BAA	Broad Agency Announcement
BoNT	Botulinum Neurotoxin
BPE	Biomedical Performance Enhancement
BSV	Biosurveillance
BSVE	Biosurveillance Ecosystem
CASEVAC	Casualty Evacuation
CCCRP	Combat Casualty Care Research Program
CDE	Common Data Element
CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
CICA	Competition in Contracting Act
CIH	Complementary and Integrative Health
CPG	Clinical Practice Guidelines
CFR	Code of Federal Regulations
CNACI	Child Care National Agency Check and Inquiries
COI	Conflict of Interest
DFARS	Defense Federal Acquisition Regulation Supplement
DOD	Department of Defense
DoDAF	Department of Defense Architecture Framework
DoDEA	Department of Defense Education Activity
DoDGARs	Department of Defense Grant and Agreement Regulations
DoDI	Department of Defense Instruction
DTRA	Defense Threat Reduction Agency
DUNS	Data Universal Numbering System
eBRAP	electronic Biomedical Research Application Portal
EC	Ethics Committee
EO	Executive Order
FAPIIS	Federal Awardee Performance and Integrity Information System
FAR	Federal Acquisition Regulation
FDA	U.S. Food and Drug Administration
FedBizOpps	Federal Business Opportunities

FFRDC	Federally Funded Research and Development Center
FITBIR	Federal Interagency Traumatic Brain Injury Research
FY	Fiscal Year
GA	Tabun
GB	Sarin
GD	Soman
GCP	Good Clinical Practices
GLP	Good Laboratory Practices
GMP	Good Manufacturing Practices
GPM/JPM	Global/Joint Patient Movement
GSA	General Services Administration
HL7	Health Level 7
HRPO	Human Research Protection Office
ICH E6	International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
ID	Identification
IDE	Investigational Device Exemption
IND	Investigational New Drug
IRB	Institutional Review Board
IT	Information Technology
JBCF	Joint Biosurveillance Common Framework
JETS	Joint Evacuation and Transport Simulation
JSTO-CBD	Joint Science and Technology Office for Chemical and Biological Defense
KP	Knowledge Product
KRL	Knowledge Readiness Level
LAR	Legally Authorized Representative
LET	Linear Energy Transfer
MBDRP	Medical Biological Defense Research Program
MCDRP	Medical Chemical Defense Research Program
MCM	Medical Countermeasure
MDO	Multi-Domain Operations
MHS	Military Health System
MIDRP	Military Infectious Diseases Research Program
MOMRP	Military Operational Medicine Research Program
MTF	Military Treatment Facility
MTR	Management, Treatment, and Rehabilitation
MUM-T	Manned-Unmanned Teaming
NATO	North Atlantic Treaty Organization

NDA	National Institute of Mental Health Data Archive
NIMH	National Institute of Mental Health
NMS	Neuromusculoskeletal
NINDS	National Institute of Neurological Disorders and Stroke
NPC	Non-Profit Corporation
NRAP	National Research Action Plan
NSOCM	NATO Special Operations Combat Medic
ORP	Office of Research Protections
PC	Prolonged Care
PI	Principal Investigator
PTSD	Post-Traumatic Stress Disorder
RHERP	Radiation Health Effects Research Program
RTD	Return to Duty
SAM	System for Award Management
SBIR	Small Business Innovation Research
SOW	Statement of Work
S&T	Science and Technology
STEM	Science, Technology, Engineering, or Mathematics
TBI	Traumatic Brain Injury
TFF	Total Force Fitness
TIA	Technology Investment Agreement
TRL	Technology Readiness Level
UDE	Unique Data Element
URL	Uniform Resource Locator
USAMRAA	U.S. Army Medical Research Acquisition Activity
USAMRDC	U.S. Army Medical Research and Development Command
USASOC	U.S. Army Special Operations Command
USC	United States Code
VA	Department of Veterans Affairs